<?xml version="1.0" encoding="UTF-8"?>
<search_results count="327154">
  <query>ALL</query>
  <!-- Additional study fields may be added over time -->
  <study rank="327001">
    <nct_id>NCT00000341</nct_id>
    <title>Evaluation of Liquid vs. Tablet Buprenorphine - 6</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Opioid-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Buprenorphine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Subjective and observer rater physiological effects of bup</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>21 Years</min_age>
    <max_age>50 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>1</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-3-0010-6</other_id>
      <other_id>Y01-3-0010-6</other_id>
    </other_ids>
    <start_date>August 1996</start_date>
    <completion_date>August 2000</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>January 12, 2017</last_update_posted>
    <locations>
      <location>Friends Research Institute, Los Angeles, California, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000341</url>
  </study>
  <study rank="327002">
    <nct_id>NCT00000340</nct_id>
    <title>Pemoline in the Treatment of Stimulant Dependence - 5</title>
    <acronym/>
    <status open="N">Withdrawn</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cocaine-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Pemoline</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Retention</outcome_measure>
      <outcome_measure>Depression</outcome_measure>
      <outcome_measure>Incidence of stimulant use</outcome_measure>
      <outcome_measure>Severity of stimulant withdrawal symptoms</outcome_measure>
      <outcome_measure>ADHD symptom severity</outcome_measure>
      <outcome_measure>Degree of drug craving</outcome_measure>
      <outcome_measure>Frequency of IV drug use and sexual risk behaviors</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>21 Years</min_age>
    <max_age>50 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-3-0010-5</other_id>
      <other_id>Y01-3-0010-5</other_id>
    </other_ids>
    <start_date>June 1996</start_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>January 12, 2017</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000340</url>
  </study>
  <study rank="327003">
    <nct_id>NCT00000339</nct_id>
    <title>Infusion Laboratory: Protocol 3 (Risperidone) - 4</title>
    <acronym/>
    <status open="N">Unknown status</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cocaine-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Risperidone</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Evidence of change in neurotoxicity based on chore</outcome_measure>
      <outcome_measure>Degree of drug craving</outcome_measure>
      <outcome_measure>History, incidence and amount of drug use</outcome_measure>
      <outcome_measure>Type and severity of stimulant withdrawal symptoms</outcome_measure>
      <outcome_measure>Characterization of study population</outcome_measure>
      <outcome_measure>Population incidence of symptoms of depression, po</outcome_measure>
      <outcome_measure>Frequency and intensity of drug use and sexual beh</outcome_measure>
      <outcome_measure>Evidence of change in subjective responses to coca</outcome_measure>
      <outcome_measure>Clinical physiological response to cocaine challen</outcome_measure>
      <outcome_measure>Degree to which study medication influences change</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>21 Years</min_age>
    <max_age>50 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>13</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Single</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-3-0010-4</other_id>
      <other_id>Y01-3-0010-4</other_id>
    </other_ids>
    <start_date>June 1996</start_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>January 11, 2017</last_update_posted>
    <locations>
      <location>Friends Research Institute, Los Angeles, California, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000339</url>
  </study>
  <study rank="327004">
    <nct_id>NCT00000338</nct_id>
    <title>Infusion Laboratory: Protocol 2 (Lisuride) - 3</title>
    <acronym/>
    <status open="N">Unknown status</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cocaine-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Lisuride</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Degree of drug craving</outcome_measure>
      <outcome_measure>History, incidence and amount of drug use</outcome_measure>
      <outcome_measure>Type and severity of stimulant withdrawal symptoms</outcome_measure>
      <outcome_measure>Characterization of study population</outcome_measure>
      <outcome_measure>Population incidence of symptoms of depression, po</outcome_measure>
      <outcome_measure>Frequency and intensity of drug use and sexual beh</outcome_measure>
      <outcome_measure>Evidence of change in neurophysiology and brain ac</outcome_measure>
      <outcome_measure>Evidence of change in subjective responses to coca</outcome_measure>
      <outcome_measure>Clinical physiological response to cocaine challen</outcome_measure>
      <outcome_measure>Degree to which study medication influences change</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>21 Years</min_age>
    <max_age>50 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>2</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-3-0010-3</other_id>
      <other_id>Y01-3-0010-3</other_id>
    </other_ids>
    <start_date>March 1996</start_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>January 11, 2017</last_update_posted>
    <locations>
      <location>Friends Research Institute, Los Angeles, California, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000338</url>
  </study>
  <study rank="327005">
    <nct_id>NCT00000337</nct_id>
    <title>Infusion Laboratory: Protocol 1 - Selegeline - 2</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cocaine-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Selegiline</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Degree of drug craving</outcome_measure>
      <outcome_measure>History, incidence and amount of drug use</outcome_measure>
      <outcome_measure>Type and severity of stimulant withdrawal symptoms</outcome_measure>
      <outcome_measure>Population incidence of symptoms of depression, possible organic brain syndrome deficits</outcome_measure>
      <outcome_measure>Frequency and intensity of drug use and sexual behaviors at risk for HIV</outcome_measure>
      <outcome_measure>Evidence of change in neurophysiology and brain activity</outcome_measure>
      <outcome_measure>Evidence of change in subjective responses to cocaine challenge</outcome_measure>
      <outcome_measure>Clinical physiological response to cocaine challenge - especially adverse effects measures</outcome_measure>
      <outcome_measure>Degree to which study medication influences changes in #6, 7 &amp; 8 above (possible efficacy measure)</outcome_measure>
      <outcome_measure>Characterization of study population</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>31 Years</min_age>
    <max_age>47 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-3-0010-2</other_id>
      <other_id>Y01-3-0010-2</other_id>
    </other_ids>
    <start_date>November 1994</start_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>January 12, 2017</last_update_posted>
    <locations>
      <location>Friends Research Institute, Los Angeles, California, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000337</url>
  </study>
  <study rank="327006">
    <nct_id>NCT00000336</nct_id>
    <title>Selegiline in Outpatient Treatment for Cocaine Dependence - 1</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cocaine-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Selegiline</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Urine toxicology for cocaine</outcome_measure>
      <outcome_measure>Self reports of cocaine and other drug use and craving</outcome_measure>
      <outcome_measure>Evidence of change in neurotoxicity based on choreoathetoid movement assessments</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>21 Years</min_age>
    <max_age>50 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-3-0010-1</other_id>
      <other_id>Y01-3-0010-1</other_id>
    </other_ids>
    <start_date>January 1995</start_date>
    <primary_completion_date>February 1996</primary_completion_date>
    <completion_date>March 1996</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>January 16, 2017</last_update_posted>
    <locations>
      <location>Friends Research Institute, Los Angeles, California, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000336</url>
  </study>
  <study rank="327007">
    <nct_id>NCT00000335</nct_id>
    <title>Activity Monitoring Assessment of Opiate Withdrawal - 4</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Opioid-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Morphine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Depression</outcome_measure>
      <outcome_measure>Anxiety</outcome_measure>
      <outcome_measure>Withdrawal severity</outcome_measure>
      <outcome_measure>Activity</outcome_measure>
      <outcome_measure>Opiate secondary withdrawal</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
      <collaborator>Washington D.C. Veterans Affairs Medical Center</collaborator>
    </sponsors>
    <gender>Male</gender>
    <min_age>21 Years</min_age>
    <max_age>55 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>U.S. Fed</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-3-0009-4</other_id>
      <other_id>Y01-3-0009-4</other_id>
    </other_ids>
    <start_date>September 30, 1995</start_date>
    <primary_completion_date>March 20, 1996</primary_completion_date>
    <completion_date>May 20, 1996</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>January 31, 2017</last_update_posted>
    <locations>
      <location>Washington DC VA, Washington, District of Columbia, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000335</url>
  </study>
  <study rank="327008">
    <nct_id>NCT00000334</nct_id>
    <title>Comparison of Buprenorphine and Methadone - 3</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Opioid-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Buprenorphine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Withdrawal severity</outcome_measure>
      <outcome_measure>Opiate agonist symptoms</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
      <collaborator>Washington D.C. Veterans Affairs Medical Center</collaborator>
    </sponsors>
    <gender>Male</gender>
    <min_age>23 Years</min_age>
    <max_age>45 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>U.S. Fed</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-3-0009-3</other_id>
      <other_id>Y01-3-0009-3</other_id>
    </other_ids>
    <start_date>December 1, 2002</start_date>
    <primary_completion_date>November 1, 2004</primary_completion_date>
    <completion_date>January 15, 2005</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>January 31, 2017</last_update_posted>
    <locations>
      <location>Washington DC VA, Washington, District of Columbia, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000334</url>
  </study>
  <study rank="327009">
    <nct_id>NCT00000333</nct_id>
    <title>Evaluation of Benztropine for Cocaine Craving - 2</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cocaine-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Benztropine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Stimulated and non-stimulated craving</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
      <collaborator>Washington D.C. Veterans Affairs Medical Center</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>22 Years</min_age>
    <max_age>48 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>U.S. Fed</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-3-0009-2</other_id>
      <other_id>Y01-3-0009-2</other_id>
    </other_ids>
    <start_date>May 2001</start_date>
    <primary_completion_date>January 2003</primary_completion_date>
    <completion_date>April 2003</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>February 24, 2017</last_update_posted>
    <locations>
      <location>Washington DC VA, Washington, District of Columbia, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000333</url>
  </study>
  <study rank="327010">
    <nct_id>NCT00000332</nct_id>
    <title>High Dose Nimodipine Treatment Adjunct - 1</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cocaine-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Nimodipine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Stimulated and non-stimulated craving</outcome_measure>
      <outcome_measure>Stimulated and non-stimulated withdrawal</outcome_measure>
      <outcome_measure>Anxiety, depression</outcome_measure>
      <outcome_measure>Heart rate</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
      <collaborator>Washington D.C. Veterans Affairs Medical Center</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>22 Years</min_age>
    <max_age>45 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>U.S. Fed</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-3-0009-1</other_id>
      <other_id>Y01-3-0009-1</other_id>
    </other_ids>
    <start_date>May 1998</start_date>
    <primary_completion_date>January 2000</primary_completion_date>
    <completion_date>April 2000</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>February 24, 2017</last_update_posted>
    <locations>
      <location>Washington DC VA, Washington, District of Columbia, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000332</url>
  </study>
  <study rank="327011">
    <nct_id>NCT00000331</nct_id>
    <title>Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment II-3 - 6</title>
    <acronym/>
    <status open="N">Withdrawn</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Heroin Dependence</condition>
      <condition>Opioid-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Test Drug</intervention>
      <intervention type="Drug">Placebo Drug</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Observed withdrawal rating</outcome_measure>
      <outcome_measure>Pupil diameter</outcome_measure>
      <outcome_measure>Drug effect characteristics</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Colorado, Denver</lead_sponsor>
      <collaborator>National Institute on Drug Abuse (NIDA)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-11160-6</other_id>
      <other_id>R01DA011160</other_id>
      <other_id>R01-11160-6</other_id>
    </other_ids>
    <start_date>December 2002</start_date>
    <primary_completion_date>December 2002</primary_completion_date>
    <completion_date>December 2002</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>May 4, 2017</last_update_posted>
    <locations>
      <location>University of Colorado Health Sciences Center, Denver, Colorado, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000331</url>
  </study>
  <study rank="327012">
    <nct_id>NCT00000330</nct_id>
    <title>Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment II-2 - 5</title>
    <acronym/>
    <status open="N">Withdrawn</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Heroin Dependence</condition>
      <condition>Opioid-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Opioid-Related Disorders</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Subjective dose estimate</outcome_measure>
      <outcome_measure>Observed withdrawal rating</outcome_measure>
      <outcome_measure>Opioid antagonist rating</outcome_measure>
      <outcome_measure>Pupil diameter</outcome_measure>
      <outcome_measure>Analog rating scale for drug effects</outcome_measure>
      <outcome_measure>Drug effect characteristics</outcome_measure>
      <outcome_measure>Drug/Money Preferences</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Colorado, Denver</lead_sponsor>
      <collaborator>National Institute on Drug Abuse (NIDA)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-11160-5</other_id>
      <other_id>R01DA011160</other_id>
      <other_id>R01-11160-5</other_id>
    </other_ids>
    <start_date>October 1999</start_date>
    <primary_completion_date>November 1999</primary_completion_date>
    <completion_date>November 1999</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>May 4, 2017</last_update_posted>
    <locations>
      <location>University of Colorado Health Sciences Center, Denver, Colorado, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000330</url>
  </study>
  <study rank="327013">
    <nct_id>NCT00000329</nct_id>
    <title>Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment II-1 - 4</title>
    <acronym/>
    <status open="N">Withdrawn</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Heroin Dependence</condition>
      <condition>Opioid-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Opioid-Related Disorders</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Subjective dose estimate</outcome_measure>
      <outcome_measure>Observed withdrawal rating</outcome_measure>
      <outcome_measure>Opioid agonist rating</outcome_measure>
      <outcome_measure>Opioid antagonist rating</outcome_measure>
      <outcome_measure>Pupil diameter</outcome_measure>
      <outcome_measure>Analog rating scale for drug effects</outcome_measure>
      <outcome_measure>Drug effect characteristics</outcome_measure>
      <outcome_measure>Drug/Money Preferences</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Colorado, Denver</lead_sponsor>
      <collaborator>National Institute on Drug Abuse (NIDA)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-11160-4</other_id>
      <other_id>R01DA011160</other_id>
      <other_id>R01-11160-4</other_id>
    </other_ids>
    <start_date>April 1999</start_date>
    <primary_completion_date>August 1999</primary_completion_date>
    <completion_date>August 1999</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>May 4, 2017</last_update_posted>
    <locations>
      <location>University of Colorado Health Sciences Center, Denver, Colorado, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000329</url>
  </study>
  <study rank="327014">
    <nct_id>NCT00000328</nct_id>
    <title>Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment III) - 3</title>
    <acronym/>
    <status open="N">Withdrawn</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Heroin Dependence</condition>
      <condition>Opioid-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Opioid-Related Disorders</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Drug use</outcome_measure>
      <outcome_measure>Retention</outcome_measure>
      <outcome_measure>Opioid agonist rating</outcome_measure>
      <outcome_measure>Opioid antagonist rating</outcome_measure>
      <outcome_measure>Compliance</outcome_measure>
      <outcome_measure>Medication identification</outcome_measure>
      <outcome_measure>Addiction Severity Index (ASI) Composite Score Rating</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Colorado, Denver</lead_sponsor>
      <collaborator>National Institute on Drug Abuse (NIDA)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-11160-3</other_id>
      <other_id>1R01DA011160</other_id>
      <other_id>R01-11160-3</other_id>
    </other_ids>
    <start_date>July 1997</start_date>
    <primary_completion_date>August 1997</primary_completion_date>
    <completion_date>August 1997</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>May 4, 2017</last_update_posted>
    <locations>
      <location>University of Colorado Health Sciences Center, Denver, Colorado, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000328</url>
  </study>
  <study rank="327015">
    <nct_id>NCT00000327</nct_id>
    <title>Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment I(2) - 2</title>
    <acronym/>
    <status open="N">Withdrawn</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Heroin Dependence</condition>
      <condition>Opioid-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Heroin Dependence</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Drug use</outcome_measure>
      <outcome_measure>Retention</outcome_measure>
      <outcome_measure>Compliance</outcome_measure>
      <outcome_measure>Dosing schedule preferences</outcome_measure>
      <outcome_measure>Analog rating scale for dosing schedule effects</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Colorado, Denver</lead_sponsor>
      <collaborator>National Institute on Drug Abuse (NIDA)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>62 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-11160-2</other_id>
      <other_id>R01DA011160</other_id>
      <other_id>R01-11160-2</other_id>
    </other_ids>
    <start_date>June 1997</start_date>
    <primary_completion_date>August 1997</primary_completion_date>
    <completion_date>August 1997</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>May 4, 2017</last_update_posted>
    <locations>
      <location>University of Colorado Health Sciences Center, Denver, Colorado, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000327</url>
  </study>
  <study rank="327016">
    <nct_id>NCT00000326</nct_id>
    <title>Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment 1 - 1</title>
    <acronym/>
    <status open="N">Withdrawn</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Heroin Dependence</condition>
      <condition>Opioid-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Heroin Dependence</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Drug use</outcome_measure>
      <outcome_measure>Retention</outcome_measure>
      <outcome_measure>Subjective dose estimate</outcome_measure>
      <outcome_measure>Observed withdrawal rating</outcome_measure>
      <outcome_measure>Opioid agonist rating</outcome_measure>
      <outcome_measure>Opioid antagonist rating</outcome_measure>
      <outcome_measure>Pupil diameter</outcome_measure>
      <outcome_measure>Compliance</outcome_measure>
      <outcome_measure>Analog rating scale for drug effects</outcome_measure>
      <outcome_measure>Drug effect characteristics</outcome_measure>
      <outcome_measure>Dose order estimate-nurse</outcome_measure>
      <outcome_measure>Dose order estimate-client</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Colorado, Denver</lead_sponsor>
      <collaborator>National Institute on Drug Abuse (NIDA)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>64 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-11160-1</other_id>
      <other_id>1R01DA011160</other_id>
      <other_id>R01-11160-1</other_id>
    </other_ids>
    <start_date>April 1997</start_date>
    <primary_completion_date>August 1997</primary_completion_date>
    <completion_date>August 1997</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>May 4, 2017</last_update_posted>
    <locations>
      <location>University of Colorado Health Sciences Center, Denver, Colorado, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000326</url>
  </study>
  <study rank="327017">
    <nct_id>NCT00000325</nct_id>
    <title>Psychostimulant Abuse - Novel Treatment Approaches - 1</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cocaine-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">Gonadorelin</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
      <collaborator>Mclean Hospital</collaborator>
    </sponsors>
    <gender>Male</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-10757-1</other_id>
      <other_id>R01-10757-1</other_id>
    </other_ids>
    <completion_date>December 2001</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>January 12, 2017</last_update_posted>
    <locations>
      <location>McLean Hospital, Dept. of Psychiatry, Belmont, Massachusetts, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000325</url>
  </study>
  <study rank="327018">
    <nct_id>NCT00000324</nct_id>
    <title>Tryptophan and Behavior Therapy for Cocaine Abuse - 1</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cocaine-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Tryptophan</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Side effects</outcome_measure>
      <outcome_measure>Retention</outcome_measure>
      <outcome_measure>Cocaine use</outcome_measure>
      <outcome_measure>Cocaine craving</outcome_measure>
      <outcome_measure>Other drug use</outcome_measure>
      <outcome_measure>Psychosocial functioning</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
      <collaborator>Johns Hopkins University</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>55 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>200</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-10754-1</other_id>
      <other_id>R01-10754-1</other_id>
    </other_ids>
    <start_date>March 1997</start_date>
    <completion_date>April 2001</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>January 12, 2017</last_update_posted>
    <locations>
      <location>Johns Hopkins University School of Medicine, Baltimore, Maryland, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000324</url>
  </study>
  <study rank="327019">
    <nct_id>NCT00000323</nct_id>
    <title>Therapeutic Potential of Kappa-Opioids Against Cocaine - 1</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cocaine-Related Disorders</condition>
    </conditions>
    <interventions/>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>21 Years</min_age>
    <max_age>50 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>10</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs/>
    <other_ids>
      <other_id>NIDA-10753-1</other_id>
      <other_id>R01-10753-1</other_id>
    </other_ids>
    <start_date>July 1996</start_date>
    <completion_date>December 1998</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>January 12, 2017</last_update_posted>
    <locations>
      <location>Johns Hopkins University (BPRU) Bayview Campus, Baltimore, Maryland, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000323</url>
  </study>
  <study rank="327020">
    <nct_id>NCT00000322</nct_id>
    <title>Tyrosine for Methamphetamine Dependence - 1</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Amphetamine-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">Tyrosine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Craving</outcome_measure>
      <outcome_measure>Drug use</outcome_measure>
      <outcome_measure>Retention</outcome_measure>
      <outcome_measure>Functioning</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>89</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-10739-1</other_id>
      <other_id>R01-10739-1</other_id>
    </other_ids>
    <start_date>April 1997</start_date>
    <completion_date>December 2001</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>January 12, 2017</last_update_posted>
    <locations>
      <location>Haight Ashbury Free Clinics, San Francisco, California, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000322</url>
  </study>
  <study rank="327021">
    <nct_id>NCT00000321</nct_id>
    <title>Methamphetamine Abuse Treatment in Patients With AIDS - 1</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Substance-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Desipramine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Craving</outcome_measure>
      <outcome_measure>Retention</outcome_measure>
      <outcome_measure>Depression</outcome_measure>
      <outcome_measure>Methamphetamine use</outcome_measure>
      <outcome_measure>Anxiety and Depression</outcome_measure>
      <outcome_measure>ASI Scales (7)</outcome_measure>
      <outcome_measure>AIDS medical care engagement</outcome_measure>
      <outcome_measure>High risk sexual behaviors</outcome_measure>
      <outcome_measure>Mood indicators</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
      <collaborator>Friends Research Institute, Inc.</collaborator>
    </sponsors>
    <gender>Male</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-10643-1</other_id>
      <other_id>R01-10643-1</other_id>
    </other_ids>
    <start_date>October 1996</start_date>
    <completion_date>December 2001</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>January 12, 2017</last_update_posted>
    <locations>
      <location>Friends Research Institute, Los Angeles, California, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000321</url>
  </study>
  <study rank="327022">
    <nct_id>NCT00000320</nct_id>
    <title>Buprenorphine Formulation Comparison: Sublingual Tablet vs. Solution - 1</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Opioid-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Buprenorphine formulation: liquid vs. tablet</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>blood level</outcome_measure>
      <outcome_measure>drug use</outcome_measure>
      <outcome_measure>craving</outcome_measure>
      <outcome_measure>withdrawal symptoms</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>120</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-10068-1</other_id>
      <other_id>R01-10068-1</other_id>
    </other_ids>
    <start_date>October 1997</start_date>
    <primary_completion_date>August 1999</primary_completion_date>
    <completion_date>August 1999</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>January 12, 2017</last_update_posted>
    <locations>
      <location>Friends Research Institute, Los Angeles, California, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000320</url>
  </study>
  <study rank="327023">
    <nct_id>NCT00000319</nct_id>
    <title>Buprenorphine Maintenance Dose Schedule and Treatment Setting - 2</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Opioid-Related Disorders</condition>
      <condition>Substance-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Buprenorphine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Depression</outcome_measure>
      <outcome_measure>Withdrawal symptoms</outcome_measure>
      <outcome_measure>Opioid and cocaine use</outcome_measure>
      <outcome_measure>Social and psychological functioning</outcome_measure>
      <outcome_measure>AIDS risk behavior</outcome_measure>
      <outcome_measure>Opiate withdrawal symptoms</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
      <collaborator>Yale University</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>21 Years</min_age>
    <max_age>55 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-09803-2</other_id>
      <other_id>R01-09803-2</other_id>
    </other_ids>
    <start_date>June 1996</start_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>August 17, 2005</last_update_posted>
    <locations>
      <location>APT Residential Services Division, New Haven, Connecticut, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000319</url>
  </study>
  <study rank="327024">
    <nct_id>NCT00000318</nct_id>
    <title>Buprenorphine Maintenance Dose Schedule and Treatment Setting - 1</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Opioid-Related Disorders</condition>
      <condition>Substance-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Buprenorphine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Opioid and cocaine use</outcome_measure>
      <outcome_measure>Social and psychological functioning</outcome_measure>
      <outcome_measure>AIDS risk behavior</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
      <collaborator>Yale University</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>21 Years</min_age>
    <max_age>55 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>202</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Factorial Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-09803-1</other_id>
      <other_id>R01-09803-1</other_id>
    </other_ids>
    <start_date>December 1994</start_date>
    <primary_completion_date>March 2004</primary_completion_date>
    <completion_date>August 2007</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>January 12, 2017</last_update_posted>
    <locations>
      <location>APT Residential Services Division, New Haven, Connecticut, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000318</url>
  </study>
  <study rank="327025">
    <nct_id>NCT00000317</nct_id>
    <title>Early Phase II Trials for Cocaine Medication Development - 1</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cocaine-Related Disorders</condition>
      <condition>Substance-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Risperidone</intervention>
      <intervention type="Drug">Placebo</intervention>
      <intervention type="Behavioral">Relapse prevention counseling</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Side effects</outcome_measure>
      <outcome_measure>Craving</outcome_measure>
      <outcome_measure>Drug use</outcome_measure>
      <outcome_measure>Retention</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>New York State Psychiatric Institute</lead_sponsor>
      <collaborator>National Institute on Drug Abuse (NIDA)</collaborator>
      <collaborator>Research Foundation for Mental Hygiene, Inc.</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>60 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>31</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>#3124</other_id>
      <other_id>R01DA009582</other_id>
    </other_ids>
    <start_date>August 1996</start_date>
    <primary_completion_date>July 1999</primary_completion_date>
    <completion_date>July 1999</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>June 26, 2017</last_update_posted>
    <locations>
      <location>NYS Psychiatric Institute, New York, New York, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000317</url>
  </study>
  <study rank="327026">
    <nct_id>NCT00000316</nct_id>
    <title>Human Dopamine Transported Imaging in Cocaine Abuse: 2 - 2</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cocaine-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Cocaine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Psychological effects</outcome_measure>
      <outcome_measure>Effects of investigational drug</outcome_measure>
      <outcome_measure>Physiological changes in: heart rate and blood pre</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
      <collaborator>Johns Hopkins University</collaborator>
    </sponsors>
    <gender>Male</gender>
    <min_age>21 Years</min_age>
    <max_age>45 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-09482-2</other_id>
      <other_id>R01-09482-2</other_id>
    </other_ids>
    <start_date>August 1996</start_date>
    <completion_date>December 2001</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>January 12, 2017</last_update_posted>
    <locations>
      <location>Johns Hopkins University, Baltimore, Maryland, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000316</url>
  </study>
  <study rank="327027">
    <nct_id>NCT00000315</nct_id>
    <title>Human Dopamine Transported Imaging in Cocaine Abuse: 1 - 1</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cocaine-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Cocaine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Physiological changes in: heart rate and blood pressure</outcome_measure>
      <outcome_measure>Subjective effects of cocaine inducements and withdrawal</outcome_measure>
      <outcome_measure>Psychological effects</outcome_measure>
      <outcome_measure>Effects of investigational drug</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
      <collaborator>Johns Hopkins University</collaborator>
    </sponsors>
    <gender>Male</gender>
    <min_age>21 Years</min_age>
    <max_age>45 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-09482-1</other_id>
      <other_id>R01-09482-1</other_id>
    </other_ids>
    <start_date>November 1996</start_date>
    <completion_date>December 2001</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>January 12, 2017</last_update_posted>
    <locations>
      <location>Johns Hopkins University, Baltimore, Maryland, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000315</url>
  </study>
  <study rank="327028">
    <nct_id>NCT00000314</nct_id>
    <title>M-CPP and Fenfluramine in Cocaine Addicts - 3</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cocaine-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">M-CPP</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Drug use</outcome_measure>
      <outcome_measure>Hospitalization, arrests, jail, employment, psychiataric symptoms</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
      <collaborator>VA Office of Research and Development</collaborator>
    </sponsors>
    <gender>Male</gender>
    <min_age>25 Years</min_age>
    <max_age>50 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>U.S. Fed</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-09468-3</other_id>
      <other_id>R01-09468-3</other_id>
    </other_ids>
    <start_date>September 1994</start_date>
    <primary_completion_date>August 1999</primary_completion_date>
    <completion_date>August 1999</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>January 18, 2017</last_update_posted>
    <locations>
      <location>VA Medical Center, Brooklyn, New York, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000314</url>
  </study>
  <study rank="327029">
    <nct_id>NCT00000313</nct_id>
    <title>Predictive Values of Serotonergic Alterations for Outcome - 2</title>
    <acronym/>
    <status open="N">Terminated</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cocaine-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Fenfluramine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Side effects</outcome_measure>
      <outcome_measure>Neuroendocrine changes</outcome_measure>
      <outcome_measure>Psychological changes</outcome_measure>
      <outcome_measure>Craving</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
      <collaborator>VA Office of Research and Development</collaborator>
    </sponsors>
    <gender>Male</gender>
    <min_age>25 Years</min_age>
    <max_age>50 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>U.S. Fed</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-09468-2</other_id>
      <other_id>R01-09468-2</other_id>
    </other_ids>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>January 12, 2017</last_update_posted>
    <locations>
      <location>VA Medical Center, Brooklyn, New York, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000313</url>
  </study>
  <study rank="327030">
    <nct_id>NCT00000312</nct_id>
    <title>Alterations in Serotonergic Functions in Cocaine Addicts - 1</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cocaine-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">M-CPP</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Side effects</outcome_measure>
      <outcome_measure>Neuroendocrine changes</outcome_measure>
      <outcome_measure>Psychological changes</outcome_measure>
      <outcome_measure>Craving</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
      <collaborator>US Department of Veterans Affairs</collaborator>
    </sponsors>
    <gender>Male</gender>
    <min_age>25 Years</min_age>
    <max_age>50 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>U.S. Fed</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-09468-1</other_id>
      <other_id>R01-09468-1</other_id>
    </other_ids>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>June 24, 2005</last_update_posted>
    <locations>
      <location>VA Medical Center, Brooklyn, New York, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000312</url>
  </study>
  <study rank="327031">
    <nct_id>NCT00000311</nct_id>
    <title>Combining Behavioral Treatment With Agonist Maintenance - 1</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cocaine-Related Disorders</condition>
      <condition>Opioid-Related Disorders</condition>
      <condition>Substance-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Buprenorphine</intervention>
      <intervention type="Drug">methadone</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Depression</outcome_measure>
      <outcome_measure>Withdrawal symptoms</outcome_measure>
      <outcome_measure>Opioid and cocaine use</outcome_measure>
      <outcome_measure>Social and psychological functioning</outcome_measure>
      <outcome_measure>AIDS risk behavior</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Yale University</lead_sponsor>
      <collaborator>National Institute on Drug Abuse (NIDA)</collaborator>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>168</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Factorial Assignment</study_design>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-09413-1</other_id>
      <other_id>R01DA009413</other_id>
      <other_id>R01-09413-1</other_id>
    </other_ids>
    <start_date>February 1995</start_date>
    <primary_completion_date>February 1999</primary_completion_date>
    <completion_date>February 1999</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>January 17, 2018</last_update_posted>
    <locations>
      <location>APT Residential Services Division, New Haven, Connecticut, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000311</url>
  </study>
  <study rank="327032">
    <nct_id>NCT00000310</nct_id>
    <title>Serotonin/Dopamine Antagonism of Cocaine Effect: 2 - 2</title>
    <acronym/>
    <status open="N">Terminated</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cocaine-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Risperidone</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Urine toxicology for cocaine</outcome_measure>
      <outcome_measure>Analog mood scales</outcome_measure>
      <outcome_measure>POMS</outcome_measure>
      <outcome_measure>EPS sx</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
      <collaborator>VA Boston Healthcare System</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>50 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>U.S. Fed</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-09330-2</other_id>
      <other_id>R01-09330-2</other_id>
    </other_ids>
    <start_date>January 1996</start_date>
    <primary_completion_date>March 1996</primary_completion_date>
    <completion_date>March 1996</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>January 16, 2017</last_update_posted>
    <locations>
      <location>Brown University School of Medicine, Providence, Rhode Island, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000310</url>
  </study>
  <study rank="327033">
    <nct_id>NCT00000309</nct_id>
    <title>Serotonin/Dopamine Antagonism of Cocaine Effect: 1 - 1</title>
    <acronym/>
    <status open="N">Terminated</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cocaine-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Risperidone</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Analog mood scales</outcome_measure>
      <outcome_measure>POMS</outcome_measure>
      <outcome_measure>EPS sx</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Butler Hospital</lead_sponsor>
      <collaborator>National Institute on Drug Abuse (NIDA)</collaborator>
      <collaborator>VA Boston Healthcare System</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>50 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
      <funded_by>U.S. Fed</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-09330-1</other_id>
      <other_id>R01DA009330</other_id>
      <other_id>R01-09330-1</other_id>
    </other_ids>
    <start_date>August 1994</start_date>
    <primary_completion_date>January 2000</primary_completion_date>
    <completion_date>January 2000</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>July 24, 2015</last_update_posted>
    <locations>
      <location>Brown University School of Medicine, Providence, Rhode Island, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000309</url>
  </study>
  <study rank="327034">
    <nct_id>NCT00000308</nct_id>
    <title>Dextroamphetamine-Cocaine Behavioral Intervention - 5</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cocaine-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Dextroamphetamine</intervention>
      <intervention type="Drug">D-amphetamine</intervention>
      <intervention type="Drug">placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Verifiable cocaine abstinence</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
      <collaborator>University of Texas</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>45 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>54</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-09262-5</other_id>
      <other_id>P50-09262-5</other_id>
    </other_ids>
    <start_date>September 1995</start_date>
    <primary_completion_date>September 2000</primary_completion_date>
    <completion_date>September 2000</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>January 12, 2017</last_update_posted>
    <locations>
      <location>University of Texas Health Science Center, Houston, Texas, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000308</url>
  </study>
  <study rank="327035">
    <nct_id>NCT00000307</nct_id>
    <title>Naltrexone as Adjunct in Alcoholic Cocaine Dependent Patients - 4</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alcohol-Related Disorders</condition>
      <condition>Cocaine-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Naltrexone</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Verified abstinence from cocaine</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
      <collaborator>University of Texas</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>50 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-09262-4</other_id>
      <other_id>P50-09262-4</other_id>
    </other_ids>
    <start_date>April 2003</start_date>
    <primary_completion_date>April 2007</primary_completion_date>
    <completion_date>April 2007</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>January 12, 2017</last_update_posted>
    <locations>
      <location>University of Texas Health Science Center, Houston, Texas, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000307</url>
  </study>
  <study rank="327036">
    <nct_id>NCT00000306</nct_id>
    <title>Dextroamphetamine as Adjunct in Cocaine/Opiate Dependent Patients - 3</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cocaine-Related Disorders</condition>
      <condition>Opioid-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Dextroamphetamine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Craving</outcome_measure>
      <outcome_measure>Drug use</outcome_measure>
      <outcome_measure>Medication compliance</outcome_measure>
      <outcome_measure>Retention</outcome_measure>
      <outcome_measure>Addiction severity</outcome_measure>
      <outcome_measure>Mood indicators</outcome_measure>
      <outcome_measure>Psychiatric interview</outcome_measure>
      <outcome_measure>Effectiveness measures including psycho-social variables, side effects, and self-reported measures.</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
      <collaborator>University of Texas</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>45 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>140</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-09262-3</other_id>
      <other_id>P50-09262-3</other_id>
    </other_ids>
    <start_date>September 1994</start_date>
    <completion_date>September 2001</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>January 12, 2017</last_update_posted>
    <locations>
      <location>University of Texas Health Science Center, Houston, Texas, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000306</url>
  </study>
  <study rank="327037">
    <nct_id>NCT00000305</nct_id>
    <title>Amphetamine Cocaine Interaction Study - 2</title>
    <acronym/>
    <status open="N">Terminated</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cocaine-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Dextroamphetamine</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>The University of Texas Health Science Center, Houston</lead_sponsor>
      <collaborator>National Institute on Drug Abuse (NIDA)</collaborator>
      <collaborator>University of Texas</collaborator>
    </sponsors>
    <gender>Male</gender>
    <min_age>18 Years</min_age>
    <max_age>45 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-09262-2</other_id>
      <other_id>P50DA009262</other_id>
      <other_id>P50-09262-2</other_id>
    </other_ids>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>May 18, 2012</last_update_posted>
    <locations>
      <location>University of Texas Health Science Center, Houston, Texas, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000305</url>
  </study>
  <study rank="327038">
    <nct_id>NCT00000304</nct_id>
    <title>Dextroamphetamine as an Adjunct in Cocaine Treatment - 1</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cocaine-Related Disorders</condition>
      <condition>Substance-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Dextroamphetamine</intervention>
      <intervention type="Drug">D-Amphetamine</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>verifiable cocaine abstinence</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
      <collaborator>University of Texas</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>45 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>120</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-09262-1</other_id>
      <other_id>P50-09262-1</other_id>
    </other_ids>
    <start_date>August 1997</start_date>
    <primary_completion_date>August 2001</primary_completion_date>
    <completion_date>August 2001</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>January 12, 2017</last_update_posted>
    <locations>
      <location>University of Texas Health Science Center, Houston, Texas, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000304</url>
  </study>
  <study rank="327039">
    <nct_id>NCT00000303</nct_id>
    <title>Rapid Evaluation of Baclofen for Treatment of Cocaine Abuse/Dependence - 6</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cocaine-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Baclofen</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Retention</outcome_measure>
      <outcome_measure>Cocaine use</outcome_measure>
      <outcome_measure>Cocaine craving</outcome_measure>
      <outcome_measure>Psychosocial progress</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of California, Los Angeles</lead_sponsor>
      <collaborator>National Institute on Drug Abuse (NIDA)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-09260-6</other_id>
      <other_id>P50DA009260</other_id>
      <other_id>P50-09260-6</other_id>
    </other_ids>
    <start_date>October 1997</start_date>
    <primary_completion_date>May 1999</primary_completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>July 11, 2016</last_update_posted>
    <locations>
      <location>Friends Research Institute, Los Angeles, California, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000303</url>
  </study>
  <study rank="327040">
    <nct_id>NCT00000302</nct_id>
    <title>Study Comparing Liquid and Tablet Buprenorphine Formulations - 5</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Heroin Dependence</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Buprenorphine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Drug use</outcome_measure>
      <outcome_measure>Retention</outcome_measure>
      <outcome_measure>Drug craving</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>21 Years</min_age>
    <max_age>50 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-09260-5</other_id>
      <other_id>P50-09260-5</other_id>
    </other_ids>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>November 7, 2005</last_update_posted>
    <locations>
      <location>Friends Research Institute, Los Angeles, California, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000302</url>
  </study>
  <study rank="327041">
    <nct_id>NCT00000301</nct_id>
    <title>Rapid Evaluation of Amantadine for Treatment of Cocaine Abuse/Dependence - 4</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cocaine-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Amantadine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Retention</outcome_measure>
      <outcome_measure>Cocaine use</outcome_measure>
      <outcome_measure>Cocaine craving</outcome_measure>
      <outcome_measure>Psychosocial progress</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of California, Los Angeles</lead_sponsor>
      <collaborator>National Institute on Drug Abuse (NIDA)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-09260-4</other_id>
      <other_id>P50DA009260</other_id>
      <other_id>P50-09260-4</other_id>
    </other_ids>
    <start_date>March 1996</start_date>
    <primary_completion_date>June 1998</primary_completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>July 11, 2016</last_update_posted>
    <locations>
      <location>Friends Research Institute, Los Angeles, California, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000301</url>
  </study>
  <study rank="327042">
    <nct_id>NCT00000300</nct_id>
    <title>Feasibility Study of Take-Home LAAM Medication - 3</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Opioid-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">LAAM</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Drug use</outcome_measure>
      <outcome_measure>Retention</outcome_measure>
      <outcome_measure>Increased prosocial behaviors</outcome_measure>
      <outcome_measure>Decreased frequency of HIV related behavior</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of California, Los Angeles</lead_sponsor>
      <collaborator>National Institute on Drug Abuse (NIDA)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>99 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-09260-3</other_id>
      <other_id>P50DA009260</other_id>
      <other_id>P50-09260-3</other_id>
    </other_ids>
    <start_date>March 1995</start_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>November 1, 2017</last_update_posted>
    <locations>
      <location>Friends Research Institute, Los Angeles, California, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000300</url>
  </study>
  <study rank="327043">
    <nct_id>NCT00000299</nct_id>
    <title>Rapid Opiate Detoxification and Naltrexone Induction Using Buprenorphine - 2</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Opioid-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Buprenorphine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Opiate craving</outcome_measure>
      <outcome_measure>Opiate withdrawal symptoms</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of California, Los Angeles</lead_sponsor>
      <collaborator>National Institute on Drug Abuse (NIDA)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>21 Years</min_age>
    <max_age>50 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>12</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Single (Participant)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-09260-2</other_id>
      <other_id>P50DA009260</other_id>
      <other_id>P50-09260-2</other_id>
    </other_ids>
    <start_date>October 2008</start_date>
    <primary_completion_date>November 2009</primary_completion_date>
    <completion_date>November 2009</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>January 29, 2016</last_update_posted>
    <locations>
      <location>Friends Research Institute, Los Angeles, California, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000299</url>
  </study>
  <study rank="327044">
    <nct_id>NCT00000298</nct_id>
    <title>Buprenorphine Combination Tablet Feasibility - 1</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Opioid-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Buprenorphine/naloxone</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Withdrawal symptoms</outcome_measure>
      <outcome_measure>Opiate use</outcome_measure>
      <outcome_measure>Opiate craving</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>21 Years</min_age>
    <max_age>50 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-09260-1</other_id>
      <other_id>P50-09260-1</other_id>
    </other_ids>
    <start_date>August 1995</start_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>August 17, 2005</last_update_posted>
    <locations>
      <location>Friends Research Institute, Los Angeles, California, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000298</url>
  </study>
  <study rank="327045">
    <nct_id>NCT00000297</nct_id>
    <title>Effects of Labetalol on Nicotine Administration in Humans - 14</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Tobacco Use Disorder</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Labetalol</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Subjective</outcome_measure>
      <outcome_measure>Physiologic measures</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
      <collaborator>University of Minnesota</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>21 Years</min_age>
    <max_age>55 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-09259-14</other_id>
      <other_id>P50-09259-14</other_id>
    </other_ids>
    <start_date>October 1998</start_date>
    <completion_date>December 2001</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>January 12, 2017</last_update_posted>
    <locations>
      <location>University of Minnesota, Minneapolis, Minnesota, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000297</url>
  </study>
  <study rank="327046">
    <nct_id>NCT00000296</nct_id>
    <title>Role of Metabolites in Nicotine Dependence (4) - 13</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Tobacco Use Disorder</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Cotinine fumarate</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Subjective effects</outcome_measure>
      <outcome_measure>Physiological effects</outcome_measure>
      <outcome_measure>Behavioral</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
      <collaborator>University of Minnesota</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>21 Years</min_age>
    <max_age>45 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-09259-13</other_id>
      <other_id>P50-09259-13</other_id>
    </other_ids>
    <start_date>November 1997</start_date>
    <completion_date>December 2001</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>January 12, 2017</last_update_posted>
    <locations>
      <location>University of Minnesota, Minneapolis, Minnesota, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000296</url>
  </study>
  <study rank="327047">
    <nct_id>NCT00000295</nct_id>
    <title>Progesterone Treatment in Female Smokers - 12</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Tobacco Use Disorder</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Micronized Progesterone</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Behavioral</outcome_measure>
      <outcome_measure>Subjective</outcome_measure>
      <outcome_measure>Biochemical</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
      <collaborator>University of Minnesota</collaborator>
    </sponsors>
    <gender>Female</gender>
    <min_age>21 Years</min_age>
    <max_age>45 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-09259-12</other_id>
      <other_id>P50-09259-12</other_id>
    </other_ids>
    <start_date>April 1999</start_date>
    <completion_date>December 2001</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>January 12, 2017</last_update_posted>
    <locations>
      <location>University of Minnesota, Minneapolis, Minnesota, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000295</url>
  </study>
  <study rank="327048">
    <nct_id>NCT00000294</nct_id>
    <title>Effects of Carvedilol on Cocaine Use in Humans - 11</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cocaine-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Carvedilol</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Behavioral</outcome_measure>
      <outcome_measure>Subjective</outcome_measure>
      <outcome_measure>Physiologic measures</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
      <collaborator>University of Minnesota</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>20 Years</min_age>
    <max_age>55 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-09259-11</other_id>
      <other_id>P50-09259-11</other_id>
    </other_ids>
    <start_date>September 1998</start_date>
    <completion_date>December 2001</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>January 12, 2017</last_update_posted>
    <locations>
      <location>University of Minnesota, Minneapolis, Minnesota, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000294</url>
  </study>
  <study rank="327049">
    <nct_id>NCT00000293</nct_id>
    <title>Effect of Nefazodone on Relapse in Females With Cocaine Abuse - 10</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cocaine-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Nefazodone</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Retention</outcome_measure>
      <outcome_measure>Primary drug use</outcome_measure>
      <outcome_measure>Depression (secondary)</outcome_measure>
      <outcome_measure>Relapse</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
      <collaborator>University of Minnesota</collaborator>
    </sponsors>
    <gender>Female</gender>
    <min_age>18 Years</min_age>
    <max_age>55 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-09259-10</other_id>
      <other_id>P50-09259-10</other_id>
    </other_ids>
    <start_date>January 1999</start_date>
    <completion_date>December 2001</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>January 12, 2017</last_update_posted>
    <locations>
      <location>University of Minnesota, Minneapolis, Minnesota, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000293</url>
  </study>
  <study rank="327050">
    <nct_id>NCT00000292</nct_id>
    <title>Acute Withdrawal From Smoked Cocaine - 9</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cocaine-Related Disorders</condition>
      <condition>Substance Withdrawal Syndrome</condition>
      <condition>Substance-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">Cocaine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Behavioral</outcome_measure>
      <outcome_measure>Subjective</outcome_measure>
      <outcome_measure>Physiological measures</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
      <collaborator>University of Minnesota</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>21 Years</min_age>
    <max_age>45 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-09259-9</other_id>
      <other_id>P50-09259-9</other_id>
    </other_ids>
    <start_date>April 1996</start_date>
    <completion_date>December 2001</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>January 12, 2017</last_update_posted>
    <locations>
      <location>University of Minnesota, Minneapolis, Minnesota, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000292</url>
  </study>
  <study rank="327051">
    <nct_id>NCT00000291</nct_id>
    <title>Effects of Labetalol on Human Cocaine Use - 8</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cocaine-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Labetalol</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Subjective</outcome_measure>
      <outcome_measure>Physiological measures</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
      <collaborator>University of Minnesota</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>20 Years</min_age>
    <max_age>45 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-09259-8</other_id>
      <other_id>P50-09259-8</other_id>
    </other_ids>
    <start_date>October 1997</start_date>
    <completion_date>December 2001</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>January 12, 2017</last_update_posted>
    <locations>
      <location>University of Minnesota, Minneapolis, Minnesota, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000291</url>
  </study>
  <study rank="327052">
    <nct_id>NCT00000290</nct_id>
    <title>Stress Hormones and Human Cocaine Use - 7</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cocaine-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Cocaine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Physiological measures</outcome_measure>
      <outcome_measure>Biochemical</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
      <collaborator>University of Minnesota</collaborator>
    </sponsors>
    <gender>Male</gender>
    <min_age>20 Years</min_age>
    <max_age>45 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-09259-7</other_id>
      <other_id>P50-09259-7</other_id>
    </other_ids>
    <start_date>May 1997</start_date>
    <completion_date>December 2001</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>January 12, 2017</last_update_posted>
    <locations>
      <location>University of Minnesota, Minneapolis, Minnesota, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000290</url>
  </study>
  <study rank="327053">
    <nct_id>NCT00000289</nct_id>
    <title>Role of Metabolites in Nicotine Dependence (3) - 6</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Tobacco Use Disorder</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ondansetron</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Subjective effects</outcome_measure>
      <outcome_measure>Physiological effects</outcome_measure>
      <outcome_measure>Performance effects</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
      <collaborator>University of Minnesota</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>21 Years</min_age>
    <max_age>45 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-09259-6</other_id>
      <other_id>P50-09259-6</other_id>
    </other_ids>
    <start_date>May 1998</start_date>
    <completion_date>December 2001</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>January 12, 2017</last_update_posted>
    <locations>
      <location>University of Minnesota, Minneapolis, Minnesota, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000289</url>
  </study>
  <study rank="327054">
    <nct_id>NCT00000288</nct_id>
    <title>Role of Metabolites in Nicotine Dependence (2) - 5</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Tobacco Use Disorder</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Cotinine fumarate</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Subjective effects</outcome_measure>
      <outcome_measure>Physiological effects</outcome_measure>
      <outcome_measure>Behavioral</outcome_measure>
      <outcome_measure>Subjective</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
      <collaborator>University of Minnesota</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>21 Years</min_age>
    <max_age>45 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-09259-5</other_id>
      <other_id>P50-09259-5</other_id>
    </other_ids>
    <start_date>December 1995</start_date>
    <completion_date>December 2002</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>January 12, 2017</last_update_posted>
    <locations>
      <location>University of Minnesota, Minneapolis, Minnesota, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000288</url>
  </study>
  <study rank="327055">
    <nct_id>NCT00000287</nct_id>
    <title>Relapse Patterns in Female Cocaine Users - 4</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cocaine-Related Disorders</condition>
    </conditions>
    <interventions/>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
      <collaborator>University of Minnesota</collaborator>
    </sponsors>
    <gender>Female</gender>
    <min_age>18 Years</min_age>
    <max_age>60 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs/>
    <other_ids>
      <other_id>NIDA-09259-4</other_id>
      <other_id>P50-09259-4</other_id>
    </other_ids>
    <start_date>February 1995</start_date>
    <primary_completion_date>December 2001</primary_completion_date>
    <completion_date>December 2001</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>January 12, 2017</last_update_posted>
    <locations>
      <location>University of Minnesota, Minneapolis, Minnesota, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000287</url>
  </study>
  <study rank="327056">
    <nct_id>NCT00000286</nct_id>
    <title>Effects of Nefazodone on Treatment of Female Cocaine Abusers - 3</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cocaine-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Nefazodone</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Craving</outcome_measure>
      <outcome_measure>Drug use</outcome_measure>
      <outcome_measure>Depression</outcome_measure>
      <outcome_measure>Life functioning</outcome_measure>
      <outcome_measure>HIV risk behaviors</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
      <collaborator>University of Minnesota</collaborator>
    </sponsors>
    <gender>Female</gender>
    <min_age>18 Years</min_age>
    <max_age>55 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-09259-3</other_id>
      <other_id>P50-09259-3</other_id>
    </other_ids>
    <start_date>December 1996</start_date>
    <completion_date>December 2001</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>January 12, 2017</last_update_posted>
    <locations>
      <location>University of Minnesota, Minneapolis, Minnesota, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000286</url>
  </study>
  <study rank="327057">
    <nct_id>NCT00000285</nct_id>
    <title>Effects of Phenytoin on Cocaine Use in Humans - 2</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cocaine-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Phenytoin</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Subjective effects</outcome_measure>
      <outcome_measure>Physiological effects</outcome_measure>
      <outcome_measure>Behavioral</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
      <collaborator>University of Minnesota</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>20 Years</min_age>
    <max_age>45 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-09259-2</other_id>
      <other_id>P50-09259-2</other_id>
    </other_ids>
    <start_date>May 1996</start_date>
    <completion_date>December 2001</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>January 12, 2017</last_update_posted>
    <locations>
      <location>University of Minnesota, Minneapolis, Minnesota, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000285</url>
  </study>
  <study rank="327058">
    <nct_id>NCT00000284</nct_id>
    <title>Role of Metabolites in Nicotine Dependence (1) - 1</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Tobacco Use Disorder</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Cotinine fumarate</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Subjective effects</outcome_measure>
      <outcome_measure>Physiological effects</outcome_measure>
      <outcome_measure>Performance effects</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
      <collaborator>University of Minnesota</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>21 Years</min_age>
    <max_age>45 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-09259-1</other_id>
      <other_id>P50-09259-1</other_id>
    </other_ids>
    <start_date>February 1995</start_date>
    <completion_date>December 2001</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>January 12, 2017</last_update_posted>
    <locations>
      <location>University of Minnesota, Minneapolis, Minnesota, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000284</url>
  </study>
  <study rank="327059">
    <nct_id>NCT00000282</nct_id>
    <title>Pemoline for Cocaine Abuse - 7</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cocaine-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Pemoline</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Side effects</outcome_measure>
      <outcome_measure>Drug use</outcome_measure>
      <outcome_measure>Retention</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Yale University</lead_sponsor>
      <collaborator>National Institute on Drug Abuse (NIDA)</collaborator>
      <collaborator>VA Connecticut Healthcare System</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
      <funded_by>U.S. Fed</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-09250-7</other_id>
      <other_id>P50DA009250</other_id>
      <other_id>P50-09250-7</other_id>
    </other_ids>
    <start_date>September 1994</start_date>
    <primary_completion_date>August 1999</primary_completion_date>
    <completion_date>August 1999</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>December 15, 2016</last_update_posted>
    <locations>
      <location>VA Connecticut Healthcare System, New Haven, Connecticut, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000282</url>
  </study>
  <study rank="327060">
    <nct_id>NCT00000281</nct_id>
    <title>Pharmacotherapy for Schizophrenic Drug Users - 6</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cocaine-Related Disorders</condition>
      <condition>Substance-Related Disorders</condition>
      <condition>Shcizophrenia</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">Amantadine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Drug use</outcome_measure>
      <outcome_measure>Retention</outcome_measure>
      <outcome_measure>Psychological symptoms</outcome_measure>
      <outcome_measure>Schizophrenic symptoms</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Yale University</lead_sponsor>
      <collaborator>National Institute on Drug Abuse (NIDA)</collaborator>
      <collaborator>VA Connecticut Healthcare System</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>55 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
      <funded_by>U.S. Fed</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-09250-6</other_id>
      <other_id>P50DA009250</other_id>
      <other_id>P50-09250-6</other_id>
    </other_ids>
    <start_date>September 1994</start_date>
    <primary_completion_date>August 1999</primary_completion_date>
    <completion_date>August 1999</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>December 15, 2016</last_update_posted>
    <locations>
      <location>VA Connecticut Healthcare System, New Haven, Connecticut, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000281</url>
  </study>
  <study rank="327061">
    <nct_id>NCT00000280</nct_id>
    <title>Glutaminergic Agents for Cocaine Abuse - 5</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cocaine-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Nimodipine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Cocaine effects</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Yale University</lead_sponsor>
      <collaborator>National Institute on Drug Abuse (NIDA)</collaborator>
      <collaborator>VA Connecticut Healthcare System</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>45 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
      <funded_by>U.S. Fed</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-09250-5</other_id>
      <other_id>P50DA009250</other_id>
      <other_id>P50-09250-5</other_id>
    </other_ids>
    <start_date>September 1994</start_date>
    <primary_completion_date>August 1999</primary_completion_date>
    <completion_date>August 1999</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>April 25, 2017</last_update_posted>
    <locations>
      <location>VA Connecticut Healthcare System, New Haven, Connecticut, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000280</url>
  </study>
  <study rank="327062">
    <nct_id>NCT00000279</nct_id>
    <title>Novel Medications for Opiate Detoxification - 4</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Opioid-Related Disorders</condition>
      <condition>Substance-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Clonidine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Withdrawal severity</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Yale University</lead_sponsor>
      <collaborator>National Institute on Drug Abuse (NIDA)</collaborator>
      <collaborator>VA Connecticut Healthcare System</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
      <funded_by>U.S. Fed</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-09250-4</other_id>
      <other_id>P50DA009250</other_id>
      <other_id>P50-09250-4</other_id>
    </other_ids>
    <start_date>September 1994</start_date>
    <primary_completion_date>August 1999</primary_completion_date>
    <completion_date>August 1999</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>July 25, 2013</last_update_posted>
    <locations>
      <location>VA Connecticut Healthcare System, New Haven, Connecticut, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000279</url>
  </study>
  <study rank="327063">
    <nct_id>NCT00000278</nct_id>
    <title>Disulfiram for Cocaine-Alcohol Abuse - 3</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alcohol-Related Disorders</condition>
      <condition>Cocaine-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Disulfiram</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Side effects</outcome_measure>
      <outcome_measure>Cocaine effects</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Yale University</lead_sponsor>
      <collaborator>National Institute on Drug Abuse (NIDA)</collaborator>
      <collaborator>VA Connecticut Healthcare System</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>50 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
      <funded_by>U.S. Fed</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-09250-3</other_id>
      <other_id>P50DA009250</other_id>
      <other_id>P50-09250-3</other_id>
    </other_ids>
    <start_date>September 1994</start_date>
    <primary_completion_date>August 1999</primary_completion_date>
    <completion_date>August 1999</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>July 25, 2013</last_update_posted>
    <locations>
      <location>VA Connecticut Healthcare System, New Haven, Connecticut, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000278</url>
  </study>
  <study rank="327064">
    <nct_id>NCT00000277</nct_id>
    <title>Mazindol for Cocaine Abuse - 2</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cocaine-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Mazindol</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Side effects</outcome_measure>
      <outcome_measure>Drug use</outcome_measure>
      <outcome_measure>Retention</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Yale University</lead_sponsor>
      <collaborator>National Institute on Drug Abuse (NIDA)</collaborator>
      <collaborator>VA Connecticut Healthcare System</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
      <funded_by>U.S. Fed</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-09250-2</other_id>
      <other_id>P50DA009250</other_id>
      <other_id>P50-09250-2</other_id>
    </other_ids>
    <start_date>September 1994</start_date>
    <primary_completion_date>August 1999</primary_completion_date>
    <completion_date>August 1999</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>July 25, 2013</last_update_posted>
    <locations>
      <location>VA Connecticut Healthcare System, New Haven, Connecticut, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000277</url>
  </study>
  <study rank="327065">
    <nct_id>NCT00000276</nct_id>
    <title>Dopamine Reuptake Inhibitors of Cocaine Abuse - 1</title>
    <acronym/>
    <status open="N">Terminated</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cocaine-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Bupropion</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Side effects</outcome_measure>
      <outcome_measure>Cocaine effects</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Yale University</lead_sponsor>
      <collaborator>National Institute on Drug Abuse (NIDA)</collaborator>
      <collaborator>VA Connecticut Healthcare System</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>45 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
      <funded_by>U.S. Fed</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-09250-1</other_id>
      <other_id>P50DA009250</other_id>
      <other_id>P50-09250-1</other_id>
    </other_ids>
    <start_date>September 1994</start_date>
    <primary_completion_date>August 1999</primary_completion_date>
    <completion_date>August 1999</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>July 25, 2013</last_update_posted>
    <locations>
      <location>VA Connecticut Healthcare System, New Haven, Connecticut, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000276</url>
  </study>
  <study rank="327066">
    <nct_id>NCT00000275</nct_id>
    <title>Cocaine Abuse and ADHD - 10</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cocaine-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Flupenthixol</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Side effects</outcome_measure>
      <outcome_measure>Drug use</outcome_measure>
      <outcome_measure>Cocaine craving</outcome_measure>
      <outcome_measure>ADHD symptoms</outcome_measure>
      <outcome_measure>Improvement in functioning</outcome_measure>
      <outcome_measure>Tolerability</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
      <collaborator>New York State Psychiatric Institute</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>55 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>16</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-09236-10</other_id>
      <other_id>P50-09236-10</other_id>
    </other_ids>
    <start_date>November 1996</start_date>
    <completion_date>March 1998</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>January 12, 2017</last_update_posted>
    <locations>
      <location>New York State Psychiatric Institute, New York, New York, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000275</url>
  </study>
  <study rank="327067">
    <nct_id>NCT00000274</nct_id>
    <title>Flupenthixol and Haloperidol for Treating Cocaine Abuse Schizophrenics - 9</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cocaine-Related Disorders</condition>
      <condition>Substance-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Flupenthixol</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Side effects</outcome_measure>
      <outcome_measure>Drug use</outcome_measure>
      <outcome_measure>Psychiatric symptoms</outcome_measure>
      <outcome_measure>Cocaine craving</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
      <collaborator>New York State Psychiatric Institute</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>45 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>60</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-09236-9</other_id>
      <other_id>P50-09236-9</other_id>
    </other_ids>
    <start_date>March 1997</start_date>
    <completion_date>May 1999</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>January 12, 2017</last_update_posted>
    <locations>
      <location>New York State Psychiatric Institute, New York, New York, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000274</url>
  </study>
  <study rank="327068">
    <nct_id>NCT00000273</nct_id>
    <title>A Laboratory Model for Heroin Abuse Medications - 8</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Heroin Dependence</condition>
      <condition>Opioid-Related Disorders</condition>
      <condition>Substance-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">opiates</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Amount drug self-administered</outcome_measure>
      <outcome_measure>Subjective responses</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>New York State Psychiatric Institute</lead_sponsor>
      <collaborator>National Institute on Drug Abuse (NIDA)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>45 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>8</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>#4857/5982R</other_id>
      <other_id>5P50DA009236-18</other_id>
    </other_ids>
    <start_date>August 1995</start_date>
    <primary_completion_date>November 2005</primary_completion_date>
    <completion_date>November 2005</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>July 5, 2017</last_update_posted>
    <locations>
      <location>Columbia University, New York, New York, United States</location>
      <location>New York State Psychiatric Institute, New York, New York, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000273</url>
  </study>
  <study rank="327069">
    <nct_id>NCT00000271</nct_id>
    <title>New Approaches to Cocaine Abuse Medications (A) - 6</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cocaine-Related Disorders</condition>
      <condition>Substance-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Desipramine</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Cocaine Use</outcome_measure>
      <outcome_measure>Depression</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>New York State Psychiatric Institute</lead_sponsor>
      <collaborator>National Institute on Drug Abuse (NIDA)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>60 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>111</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>3881</other_id>
      <other_id>5P50DA009236-18</other_id>
    </other_ids>
    <start_date>January 1995</start_date>
    <primary_completion_date>October 2002</primary_completion_date>
    <completion_date>October 2002</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>July 5, 2017</last_update_posted>
    <locations>
      <location>Research Foundation for Mental Hygiene, New York, New York, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000271</url>
  </study>
  <study rank="327070">
    <nct_id>NCT00000270</nct_id>
    <title>Brain Imaging: Cocaine Effects &amp; Medication Development - 5</title>
    <acronym/>
    <status open="N">Withdrawn</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cocaine-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Cocaine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Absolute change in rCBF at 5 &amp; 15 minutes (Xe)</outcome_measure>
      <outcome_measure>Relative change in rCBF at 5, 19, &amp; 33 minutes (O15)</outcome_measure>
      <outcome_measure>Correlated with a) subjective effects, b) venous blood level of coca, c) autonomic variables</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>New York State Psychiatric Institute</lead_sponsor>
      <collaborator>National Institute on Drug Abuse (NIDA)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>48 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-09236-5</other_id>
      <other_id>5P50DA009236-18</other_id>
      <other_id>P50-09236-5</other_id>
    </other_ids>
    <start_date>December 30, 1995</start_date>
    <primary_completion_date>December 30, 1995</primary_completion_date>
    <completion_date>December 30, 1995</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>August 2, 2017</last_update_posted>
    <locations>
      <location>New York State Psychiatric Institute, New York, New York, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000270</url>
  </study>
  <study rank="327071">
    <nct_id>NCT00000269</nct_id>
    <title>Pergolide Treatment for Substance Abusers - 4</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cocaine-Related Disorders</condition>
      <condition>Substance-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Pergolide</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Side effects</outcome_measure>
      <outcome_measure>Craving</outcome_measure>
      <outcome_measure>Drug use</outcome_measure>
      <outcome_measure>Improvement in functioning</outcome_measure>
      <outcome_measure>Tolerability</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
      <collaborator>New York State Psychiatric Institute</collaborator>
    </sponsors>
    <gender>Male</gender>
    <min_age>18 Years</min_age>
    <max_age>55 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-09236-4</other_id>
      <other_id>P50-09236-4</other_id>
    </other_ids>
    <start_date>October 1995</start_date>
    <completion_date>December 2001</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>January 12, 2017</last_update_posted>
    <locations>
      <location>New York State Psychiatric Institute, New York, New York, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000269</url>
  </study>
  <study rank="327072">
    <nct_id>NCT00000268</nct_id>
    <title>Cocaine Abuse and Attention Deficit Disorder - 3</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cocaine-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Bupropion</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Side effects</outcome_measure>
      <outcome_measure>Craving</outcome_measure>
      <outcome_measure>Drug use</outcome_measure>
      <outcome_measure>ADHD symptoms</outcome_measure>
      <outcome_measure>Improvement in functioning</outcome_measure>
      <outcome_measure>Tolerability</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
      <collaborator>New York State Psychiatric Institute</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>55 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>32</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-09236-3</other_id>
      <other_id>P50-09236-3</other_id>
    </other_ids>
    <start_date>May 1995</start_date>
    <completion_date>November 1998</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>January 12, 2017</last_update_posted>
    <locations>
      <location>New York State Psychiatric Institute, New York, New York, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000268</url>
  </study>
  <study rank="327073">
    <nct_id>NCT00000267</nct_id>
    <title>Risperidone Treatment in Dually-Diagnosed Individuals - 2</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cocaine-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Risperidone</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Side effects</outcome_measure>
      <outcome_measure>Craving</outcome_measure>
      <outcome_measure>Drug use</outcome_measure>
      <outcome_measure>Psychiatric symptoms</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
      <collaborator>New York State Psychiatric Institute</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>60 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-09236-2</other_id>
      <other_id>P50-09236-2</other_id>
    </other_ids>
    <completion_date>December 2001</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>January 12, 2017</last_update_posted>
    <locations>
      <location>New York State Psychiatric Institute, New York, New York, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000267</url>
  </study>
  <study rank="327074">
    <nct_id>NCT00000266</nct_id>
    <title>Flupenthixol Treatment in Schizophrenic Cocaine Abusers - 1</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cocaine-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Flupenthixol</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Side effects</outcome_measure>
      <outcome_measure>Craving</outcome_measure>
      <outcome_measure>Drug use</outcome_measure>
      <outcome_measure>Psychiatric symptoms</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
      <collaborator>New York State Psychiatric Institute</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-09236-1</other_id>
      <other_id>P50-09236-1</other_id>
    </other_ids>
    <start_date>August 1994</start_date>
    <completion_date>December 2001</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>January 12, 2017</last_update_posted>
    <locations>
      <location>New York State Psychiatric Institute, New York, New York, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000266</url>
  </study>
  <study rank="327075">
    <nct_id>NCT00000265</nct_id>
    <title>Subjective Effects of Nitrous Oxide in Dental Patients - 17</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Opioid-Related Disorders</condition>
      <condition>Substance-Related Disorders</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Anxiety scale</outcome_measure>
      <outcome_measure>Mood scale</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Chicago</lead_sponsor>
      <collaborator>National Institute on Drug Abuse (NIDA)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>46</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-08391-17</other_id>
      <other_id>R01DA008391</other_id>
      <other_id>R01-08391-17</other_id>
    </other_ids>
    <start_date>July 1997</start_date>
    <primary_completion_date>January 2002</primary_completion_date>
    <completion_date>January 2002</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>May 27, 2015</last_update_posted>
    <locations>
      <location>University of Chicago, Anesthesia &amp; Critical Care, Chicago, Illinois, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000265</url>
  </study>
  <study rank="327076">
    <nct_id>NCT00000264</nct_id>
    <title>Subjective/Psychomotor/ Effects of Combined Alcohol &amp; Nitrous Oxide - 16</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Opioid-Related Disorders</condition>
      <condition>Substance-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">30% Nitrous oxide</intervention>
      <intervention type="Other">0.35 g/Kg ethanol</intervention>
      <intervention type="Other">0.7 g/Kg ethanol</intervention>
      <intervention type="Other">0 g/Kg ethanol</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Mood</outcome_measure>
      <outcome_measure>Psychomotor performance</outcome_measure>
      <outcome_measure>Cognitive performance</outcome_measure>
      <outcome_measure>Choice of nitrous oxide vs placebo</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Chicago</lead_sponsor>
      <collaborator>National Institute on Drug Abuse (NIDA)</collaborator>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>8</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Double (Participant, Care Provider)</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-08391-16</other_id>
      <other_id>R01DA008391</other_id>
      <other_id>R01-08391-16</other_id>
    </other_ids>
    <start_date>September 1997</start_date>
    <primary_completion_date>October 1999</primary_completion_date>
    <completion_date>October 1999</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>May 27, 2015</last_update_posted>
    <locations>
      <location>University of Chicago, Anesthesia &amp; Critical Care, Chicago, Illinois, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000264</url>
  </study>
  <study rank="327077">
    <nct_id>NCT00000263</nct_id>
    <title>Effects of Combined Alcohol and Nitrous Oxide Intake - 15</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Opioid-Related Disorders</condition>
      <condition>Substance-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">30% Nitrous oxide</intervention>
      <intervention type="Other">0.25 g/Kg ethanol</intervention>
      <intervention type="Other">0.5 g/KG ethanol</intervention>
      <intervention type="Other">0 g/Kg ethanol</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Pain intensity, pain bothersomeness</outcome_measure>
      <outcome_measure>Mood</outcome_measure>
      <outcome_measure>Psychomotor performance</outcome_measure>
      <outcome_measure>Cognitive performance</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Chicago</lead_sponsor>
      <collaborator>National Institute on Drug Abuse (NIDA)</collaborator>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>11</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Double (Participant, Care Provider)</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-08391-15</other_id>
      <other_id>R01DA008391</other_id>
      <other_id>R01-08391-15</other_id>
    </other_ids>
    <start_date>January 1997</start_date>
    <primary_completion_date>October 1998</primary_completion_date>
    <completion_date>October 1998</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>May 27, 2015</last_update_posted>
    <locations>
      <location>University of Chicago, Anesthesia &amp; Critical Care, Chicago, Illinois, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000263</url>
  </study>
  <study rank="327078">
    <nct_id>NCT00000262</nct_id>
    <title>Effects of Combined Sevoflurane and Nitrous Oxide Inhalation - 14</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Opioid-Related Disorders</condition>
      <condition>Substance-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">30% Nitrous oxide</intervention>
      <intervention type="Drug">0.4% Sevoflurane</intervention>
      <intervention type="Drug">0.2% sevoflurane</intervention>
      <intervention type="Other">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Pain intensity, pain bothersomeness</outcome_measure>
      <outcome_measure>Mood</outcome_measure>
      <outcome_measure>Psychomotor performance</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Chicago</lead_sponsor>
      <collaborator>National Institute on Drug Abuse (NIDA)</collaborator>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Double (Participant, Care Provider)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-08391-14</other_id>
      <other_id>R01DA008391</other_id>
      <other_id>R01-08391-14</other_id>
    </other_ids>
    <start_date>November 1996</start_date>
    <primary_completion_date>February 1999</primary_completion_date>
    <completion_date>February 1999</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>May 27, 2015</last_update_posted>
    <locations>
      <location>University of Chicago, Anesthesia &amp; Critical Care, Chicago, Illinois, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000262</url>
  </study>
  <study rank="327079">
    <nct_id>NCT00000261</nct_id>
    <title>Effects of Alcohol History on Effects of Sevoflurane and Nitrous Oxide - 13</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alcohol-Related Disorders</condition>
      <condition>Opioid-Related Disorders</condition>
      <condition>Substance-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">30% Nitrous oxide</intervention>
      <intervention type="Other">Placebo</intervention>
      <intervention type="Drug">0.2% sevoflurane</intervention>
      <intervention type="Drug">0.4% sevoflurane</intervention>
      <intervention type="Drug">0.6% sevoflurane</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Mood</outcome_measure>
      <outcome_measure>Psychomotor performance</outcome_measure>
      <outcome_measure>Choice of drug vs placebo</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Chicago</lead_sponsor>
      <collaborator>National Institute on Drug Abuse (NIDA)</collaborator>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>14</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Double (Participant, Care Provider)</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-08391-13</other_id>
      <other_id>R01DA008391</other_id>
      <other_id>R01-08391-13</other_id>
    </other_ids>
    <start_date>November 1997</start_date>
    <primary_completion_date>October 1998</primary_completion_date>
    <completion_date>October 1998</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>May 27, 2015</last_update_posted>
    <locations>
      <location>University of Chicago, Anesthesia &amp; Critical Care, Chicago, Illinois, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000261</url>
  </study>
  <study rank="327080">
    <nct_id>NCT00000260</nct_id>
    <title>Effects of Behavioral Contingencies on Effects of Nitrous Oxide - 12</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Opioid-Related Disorders</condition>
      <condition>Substance-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Nitrous oxide</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Mood</outcome_measure>
      <outcome_measure>Choice of nitrous oxide vs placebo</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Chicago</lead_sponsor>
      <collaborator>National Institute on Drug Abuse (NIDA)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>21 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>18</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs/>
    <other_ids>
      <other_id>NIDA-08391-12</other_id>
      <other_id>R01DA008391</other_id>
      <other_id>R01-08391-12</other_id>
    </other_ids>
    <start_date>June 1997</start_date>
    <primary_completion_date>January 1998</primary_completion_date>
    <completion_date>January 1998</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>May 27, 2015</last_update_posted>
    <locations>
      <location>University of Chicago, Anesthesia &amp; Critical Care, Chicago, Illinois, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000260</url>
  </study>
  <study rank="327081">
    <nct_id>NCT00000259</nct_id>
    <title>Sevoflurane vs Nitrous Oxide Inhalation at Subanesthetic Concentrations - 11</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Opioid-Related Disorders</condition>
      <condition>Substance-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">15 % Nitrous oxide</intervention>
      <intervention type="Drug">0.3 % Sevoflurane</intervention>
      <intervention type="Drug">30% Nitrous oxide</intervention>
      <intervention type="Drug">0.6% Sevoflurane</intervention>
      <intervention type="Other">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Pain intensity</outcome_measure>
      <outcome_measure>Psychomotor performance</outcome_measure>
      <outcome_measure>Cognitive performance</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Chicago</lead_sponsor>
      <collaborator>National Institute on Drug Abuse (NIDA)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>21 Years</min_age>
    <max_age>39 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>12</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-08391-11</other_id>
      <other_id>R01DA008391</other_id>
      <other_id>R01-08391-11</other_id>
    </other_ids>
    <start_date>August 1996</start_date>
    <primary_completion_date>November 1997</primary_completion_date>
    <completion_date>November 1997</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>May 28, 2015</last_update_posted>
    <locations>
      <location>University of Chicago, Anesthesia &amp; Critical Care, Chicago, Illinois, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000259</url>
  </study>
  <study rank="327082">
    <nct_id>NCT00000258</nct_id>
    <title>Role of Instructions in Nitrous Oxide Effects and Choice - 10</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Opioid-Related Disorders</condition>
      <condition>Substance-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Nitrous oxide 10% &amp; placebo</intervention>
      <intervention type="Drug">Nitrous oxide 20% &amp; placebo</intervention>
      <intervention type="Drug">Nitrous oxide 30% &amp; placebo</intervention>
      <intervention type="Drug">Nitrous oxide 40% and placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Choice of nitrous oxide vs placebo</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Chicago</lead_sponsor>
      <collaborator>National Institute on Drug Abuse (NIDA)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>21 Years</min_age>
    <max_age>32 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>22</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-08391-10</other_id>
      <other_id>R01DA008391</other_id>
      <other_id>R01-08391-10</other_id>
    </other_ids>
    <start_date>April 1996</start_date>
    <primary_completion_date>November 1997</primary_completion_date>
    <completion_date>November 1997</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>May 28, 2015</last_update_posted>
    <locations>
      <location>University of Chicago, Anesthesia &amp; Critical Care, Chicago, Illinois, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000258</url>
  </study>
  <study rank="327083">
    <nct_id>NCT00000257</nct_id>
    <title>Effects of Alcohol History on Effects of Nitrous Oxide - 9</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alcohol-Related Disorders</condition>
      <condition>Opioid-Related Disorders</condition>
      <condition>Substance-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">0% N2O and 10% N2O</intervention>
      <intervention type="Drug">0% N2O and 20% N2O</intervention>
      <intervention type="Drug">0% N2O and 30% N2O</intervention>
      <intervention type="Drug">0% N2O and 40% N2O</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Choice of nitrous oxide vs placebo</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Chicago</lead_sponsor>
      <collaborator>National Institute on Drug Abuse (NIDA)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>21 Years</min_age>
    <max_age>37 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>19</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-08391-9</other_id>
      <other_id>R01DA008391</other_id>
      <other_id>R01-08391-9</other_id>
    </other_ids>
    <start_date>September 1995</start_date>
    <primary_completion_date>April 1997</primary_completion_date>
    <completion_date>April 1997</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>May 28, 2015</last_update_posted>
    <locations>
      <location>University of Chicago, Anesthesia &amp; Critical Care, Chicago, Illinois, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000257</url>
  </study>
  <study rank="327084">
    <nct_id>NCT00000256</nct_id>
    <title>Reinforcing Effects of Brief Exposures to Nitrous Oxide - 8</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Opioid-Related Disorders</condition>
      <condition>Substance-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">20% N2O</intervention>
      <intervention type="Drug">40% N2O</intervention>
      <intervention type="Drug">60% N2O</intervention>
      <intervention type="Drug">80% N2O</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Choice of nitrous oxide vs placebo</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Chicago</lead_sponsor>
      <collaborator>National Institute on Drug Abuse (NIDA)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>22 Years</min_age>
    <max_age>34 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>11</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-08391-8</other_id>
      <other_id>R01DA008391</other_id>
      <other_id>R01-08391-8</other_id>
    </other_ids>
    <start_date>August 1995</start_date>
    <primary_completion_date>November 1996</primary_completion_date>
    <completion_date>November 1996</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>May 28, 2015</last_update_posted>
    <locations>
      <location>University of Chicago, Anesthesia &amp; Critical Care, Chicago, Illinois, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000256</url>
  </study>
  <study rank="327085">
    <nct_id>NCT00000255</nct_id>
    <title>Differential Acute Tolerance Development to Effects of Nitrous Oxide - 7</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Opioid-Related Disorders</condition>
      <condition>Substance-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Nitrous oxide</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Pain intensity, pain bothersomeness</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Chicago</lead_sponsor>
      <collaborator>National Institute on Drug Abuse (NIDA)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>21 Years</min_age>
    <max_age>37 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>10</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-08391-7</other_id>
      <other_id>R01DA008391</other_id>
      <other_id>R01-08391-7</other_id>
    </other_ids>
    <start_date>April 1995</start_date>
    <primary_completion_date>May 1996</primary_completion_date>
    <completion_date>May 1996</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>May 28, 2015</last_update_posted>
    <locations>
      <location>University of Chicago, Anesthesia &amp; Critical Care, Chicago, Illinois, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000255</url>
  </study>
  <study rank="327086">
    <nct_id>NCT00000254</nct_id>
    <title>Isoflurane at Subanesthetic Concentrations - 6</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Opioid-Related Disorders</condition>
      <condition>Substance-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">40% Nitrous oxide</intervention>
      <intervention type="Other">Sham comparator</intervention>
      <intervention type="Drug">0.2% isoflurane</intervention>
      <intervention type="Drug">0.4% isoflurane</intervention>
      <intervention type="Drug">0.6% isoflurane</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Pain response</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Chicago</lead_sponsor>
      <collaborator>National Institute on Drug Abuse (NIDA)</collaborator>
    </sponsors>
    <gender>Male</gender>
    <min_age>21 Years</min_age>
    <max_age>34 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>10</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Single (Participant)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-08391-6</other_id>
      <other_id>R01DA008391</other_id>
      <other_id>R01-08391-6</other_id>
    </other_ids>
    <start_date>January 1995</start_date>
    <primary_completion_date>September 1995</primary_completion_date>
    <completion_date>September 1995</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>May 28, 2015</last_update_posted>
    <locations>
      <location>University of Chicago, Anesthesia &amp; Critical Care, Chicago, Illinois, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000254</url>
  </study>
  <study rank="327087">
    <nct_id>NCT00000253</nct_id>
    <title>Effects of Nitrous Oxide: A Dose-Response Analysis - 5</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Opioid-Related Disorders</condition>
      <condition>Substance-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">10% N2O</intervention>
      <intervention type="Drug">20% N2O</intervention>
      <intervention type="Drug">30% N2O</intervention>
      <intervention type="Drug">40% N2O</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Choice of N2O vs. placebo</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Chicago</lead_sponsor>
      <collaborator>National Institute on Drug Abuse (NIDA)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>21 Years</min_age>
    <max_age>37 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>16</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-08391-5</other_id>
      <other_id>R01DA008391</other_id>
      <other_id>R01-08391-5</other_id>
    </other_ids>
    <start_date>November 1994</start_date>
    <primary_completion_date>March 1996</primary_completion_date>
    <completion_date>March 1996</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>May 28, 2015</last_update_posted>
    <locations>
      <location>University of Chicago, Anesthesia &amp; Critical Care, Chicago, Illinois, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000253</url>
  </study>
  <study rank="327088">
    <nct_id>NCT00000252</nct_id>
    <title>Lack of Acute Tolerance Development to Effects of Nitrous Oxide - 4</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Opioid-Related Disorders</condition>
      <condition>Substance-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">0% N2O</intervention>
      <intervention type="Drug">10% N2O</intervention>
      <intervention type="Drug">20% N2O</intervention>
      <intervention type="Drug">30% N2O</intervention>
      <intervention type="Drug">40% N2O</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Psychomotor performance</outcome_measure>
      <outcome_measure>Cognitive performance</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Chicago</lead_sponsor>
      <collaborator>National Institute on Drug Abuse (NIDA)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>21 Years</min_age>
    <max_age>29 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>11</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-08391-4</other_id>
      <other_id>R01DA008391</other_id>
      <other_id>R01-08391-4</other_id>
    </other_ids>
    <start_date>June 1994</start_date>
    <primary_completion_date>June 1996</primary_completion_date>
    <completion_date>June 1996</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>May 28, 2015</last_update_posted>
    <locations>
      <location>University of Chicago, Anesthesia &amp; Critical Care, Chicago, Illinois, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000252</url>
  </study>
  <study rank="327089">
    <nct_id>NCT00000251</nct_id>
    <title>Effects of Subanesthetic Concentrations of Isoflurane/Nitrous Oxide - 3</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Opioid-Related Disorders</condition>
      <condition>Substance-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">30% N2O</intervention>
      <intervention type="Drug">0.2% isoflurane</intervention>
      <intervention type="Drug">0.4% isoflurane</intervention>
      <intervention type="Other">100% oxygen</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Logical reasoning test</outcome_measure>
      <outcome_measure>Free recall memory test</outcome_measure>
      <outcome_measure>Auditory reaction time</outcome_measure>
      <outcome_measure>Digit symbol substitution test</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Chicago</lead_sponsor>
      <collaborator>National Institute on Drug Abuse (NIDA)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>21 Years</min_age>
    <max_age>32 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>10</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Single (Participant)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-08391-3</other_id>
      <other_id>R01DA008391</other_id>
      <other_id>R01-08391-3</other_id>
    </other_ids>
    <start_date>April 1994</start_date>
    <primary_completion_date>January 1996</primary_completion_date>
    <completion_date>January 1996</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>December 2, 2015</last_update_posted>
    <locations>
      <location>University of Chicago, Anesthesia &amp; Critical Care, Chicago, Illinois, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000251</url>
  </study>
  <study rank="327090">
    <nct_id>NCT00000250</nct_id>
    <title>Cold Water Immersion Modulates Reinforcing Effects of Nitrous Oxide - 2</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Opioid-Related Disorders</condition>
      <condition>Substance-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">0% N2O</intervention>
      <intervention type="Drug">40% N2O</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Subject's choice of intervention</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Chicago</lead_sponsor>
      <collaborator>National Institute on Drug Abuse (NIDA)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>21 Years</min_age>
    <max_age>32 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>12</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Single (Participant)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-08391-2</other_id>
      <other_id>R01DA008391</other_id>
      <other_id>R01-08391-2</other_id>
    </other_ids>
    <start_date>December 1993</start_date>
    <primary_completion_date>May 1995</primary_completion_date>
    <completion_date>May 1995</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>May 28, 2015</last_update_posted>
    <locations>
      <location>University of Chicago, Anesthesia &amp; Critical Care, Chicago, Illinois, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000250</url>
  </study>
  <study rank="327091">
    <nct_id>NCT00000249</nct_id>
    <title>Effects of Subanesthetic Concentrations of Nitrous Oxide - 1</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Opioid-Related Disorders</condition>
      <condition>Substance-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">20% N2O</intervention>
      <intervention type="Drug">30% N2O</intervention>
      <intervention type="Drug">40% N2O</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Pain intensity</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Chicago</lead_sponsor>
      <collaborator>National Institute on Drug Abuse (NIDA)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>21 Years</min_age>
    <max_age>37 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>10</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-08391-1</other_id>
      <other_id>R01DA008391</other_id>
      <other_id>R01-08391-1</other_id>
    </other_ids>
    <start_date>September 1993</start_date>
    <primary_completion_date>June 1995</primary_completion_date>
    <completion_date>June 1995</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>May 28, 2015</last_update_posted>
    <locations>
      <location>University of Chicago, Anesthesia &amp; Critical Care, Chicago, Illinois, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000249</url>
  </study>
  <study rank="327092">
    <nct_id>NCT00000248</nct_id>
    <title>Dose Response Trial of Pergolide for Cocaine Dependence - 1</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cocaine-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Pergolide</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Side effects</outcome_measure>
      <outcome_measure>Drug use</outcome_measure>
      <outcome_measure>Retention</outcome_measure>
      <outcome_measure>Cocaine withdrawal</outcome_measure>
      <outcome_measure>Compliance</outcome_measure>
      <outcome_measure>Effectiveness of medication for global improvements</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Medical University of South Carolina</lead_sponsor>
      <collaborator>National Institute on Drug Abuse (NIDA)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>21 Years</min_age>
    <max_age>50 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-08355-1</other_id>
      <other_id>R01DA008355</other_id>
      <other_id>R01-08355-1</other_id>
    </other_ids>
    <start_date>February 1996</start_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>May 16, 2018</last_update_posted>
    <locations>
      <location>Medical University of South Carolina, Charleston, South Carolina, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000248</url>
  </study>
  <study rank="327093">
    <nct_id>NCT00000246</nct_id>
    <title>Rapid Benzodiazepine Detoxification Using Flumazenil - 1</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Substance-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Flumazenil</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Benzodiazepine withdrawal severity</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Yale University</lead_sponsor>
      <collaborator>National Institute on Drug Abuse (NIDA)</collaborator>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>10</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-08265-1</other_id>
      <other_id>R01DA008265</other_id>
      <other_id>R01-08265-1</other_id>
    </other_ids>
    <start_date>January 1993</start_date>
    <primary_completion_date>December 1994</primary_completion_date>
    <completion_date>December 1994</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>September 8, 2016</last_update_posted>
    <locations>
      <location>Yale University, Psychiatry, New Haven, Connecticut, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000246</url>
  </study>
  <study rank="327094">
    <nct_id>NCT00000245</nct_id>
    <title>Evaluation of a Desipramine Ceiling in Cocaine Abuse - 1</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cocaine-Related Disorders</condition>
      <condition>Substance-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Desipramine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Craving</outcome_measure>
      <outcome_measure>Retention</outcome_measure>
      <outcome_measure>Cocaine use</outcome_measure>
      <outcome_measure>Depression</outcome_measure>
      <outcome_measure>Anxiety</outcome_measure>
      <outcome_measure>Mood indicators</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
      <collaborator>Friends Research Institute, Inc.</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-08082-1</other_id>
      <other_id>R01-08082-1</other_id>
    </other_ids>
    <start_date>May 1994</start_date>
    <completion_date>December 2001</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>January 12, 2017</last_update_posted>
    <locations>
      <location>Friends Research Institute, Los Angeles, California, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000245</url>
  </study>
  <study rank="327095">
    <nct_id>NCT00000244</nct_id>
    <title>Effects of Dynorphin 1-13 on Heroin Addiction - 1</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Opioid-Related Disorders</condition>
      <condition>Substance Withdrawal Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Dynorphin 1 - 13</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Craving scale</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Minnesota</lead_sponsor>
      <collaborator>National Institute on Drug Abuse (NIDA)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>55 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-08067-1</other_id>
      <other_id>R01DA008067</other_id>
      <other_id>R01-08067-1</other_id>
    </other_ids>
    <start_date>August 1994</start_date>
    <primary_completion_date>March 1997</primary_completion_date>
    <completion_date>March 1997</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>May 27, 2015</last_update_posted>
    <locations>
      <location>U of Minnesota School of Medicine, Minneapolis, Minnesota, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000244</url>
  </study>
  <study rank="327096">
    <nct_id>NCT00000243</nct_id>
    <title>Effects of Buprenorphine/Naloxone in Treating Opioid Dependent Individuals Who Are Maintained on Methadone</title>
    <acronym/>
    <status open="N">Terminated</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Opioid-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Buprenorphine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Physiological effects</outcome_measure>
      <outcome_measure>Analog rating scale for drug effects</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>55 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>16</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-08045-1</other_id>
      <other_id>R01-08045-1</other_id>
      <other_id>DPMC</other_id>
    </other_ids>
    <start_date>September 2002</start_date>
    <completion_date>January 2004</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>January 12, 2017</last_update_posted>
    <locations>
      <location>Johns Hopkins University (BPRU) Bayview Campus, Baltimore, Maryland, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000243</url>
  </study>
  <study rank="327097">
    <nct_id>NCT00000242</nct_id>
    <title>Carbamazepine Treatment of Cocaine Dependence - 1</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cocaine-Related Disorders</condition>
      <condition>Substance-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Carbamazepine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Severity addiction</outcome_measure>
      <outcome_measure>Amount of drug use</outcome_measure>
      <outcome_measure>Affective stability</outcome_measure>
      <outcome_measure>Medication compliance</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Medical University of South Carolina</lead_sponsor>
      <collaborator>National Institute on Drug Abuse (NIDA)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-07761-1</other_id>
      <other_id>R29DA007761</other_id>
      <other_id>R29-07761-1</other_id>
    </other_ids>
    <start_date>October 1, 1992</start_date>
    <primary_completion_date>January 25, 1997</primary_completion_date>
    <completion_date>January 25, 1997</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>April 7, 2017</last_update_posted>
    <locations>
      <location>Medical University of South Carolina, Charleston, South Carolina, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000242</url>
  </study>
  <study rank="327098">
    <nct_id>NCT00000241</nct_id>
    <title>Flupenthixol Decanoate in Methamphetamine Smoking - 1</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Substance-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Flupenthixol</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Methamphetamine use</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
      <collaborator>Friends Research Institute, Inc.</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>22 Years</min_age>
    <max_age>45 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>58</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-07200-1</other_id>
      <other_id>R01-07200-1</other_id>
    </other_ids>
    <start_date>February 1994</start_date>
    <completion_date>May 1996</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>January 12, 2017</last_update_posted>
    <locations>
      <location>Friends Research Institute, Los Angeles, California, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000241</url>
  </study>
  <study rank="327099">
    <nct_id>NCT00000240</nct_id>
    <title>Combined Buprenorphine and Behavioral Treatment With and Without Contingent Reinforcement on Opioid and Cocaine Abstinence. - 22</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cocaine-Related Disorders</condition>
      <condition>Opioid-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Buprenorphine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Drug use</outcome_measure>
      <outcome_measure>Retention</outcome_measure>
      <outcome_measure>Weeks abstinent</outcome_measure>
      <outcome_measure>Weeks continuous abstinence</outcome_measure>
      <outcome_measure>Overall treatment outcome</outcome_measure>
      <outcome_measure>Opioid dependence and psychiatric status</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Vermont</lead_sponsor>
      <collaborator>National Institute on Drug Abuse (NIDA)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>23 Years</min_age>
    <max_age>47 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-06969-22</other_id>
      <other_id>R01DA006969</other_id>
      <other_id>R01-06969-22</other_id>
    </other_ids>
    <start_date>April 1999</start_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>June 3, 2015</last_update_posted>
    <locations>
      <location>Treatment Research Center, Burlington, Vermont, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000240</url>
  </study>
  <study rank="327100">
    <nct_id>NCT00000239</nct_id>
    <title>Buprenorphine Pharmacology Related to Addiction Treatment - 21</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Opioid-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Buprenorphine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Drug use</outcome_measure>
      <outcome_measure>Opioid agonist effects</outcome_measure>
      <outcome_measure>Opiate withdrawal</outcome_measure>
      <outcome_measure>Physiological changes in: pupil diameter, blood pressure, heart rate, respiration</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
      <collaborator>University of Vermont</collaborator>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-06969-21</other_id>
      <other_id>R01-06969-21</other_id>
    </other_ids>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>August 17, 2005</last_update_posted>
    <locations>
      <location>Treatment Research Center, Burlington, Vermont, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000239</url>
  </study>
  <study rank="327101">
    <nct_id>NCT00000238</nct_id>
    <title>Temporal Discounting Delayed Outcomes on Opioid-Dependent Outpatients - 20</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Opioid-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Buprenorphine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Drug use</outcome_measure>
      <outcome_measure>Money choice</outcome_measure>
      <outcome_measure>Heroin craving</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
      <collaborator>University of Vermont</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>47 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-06969-20</other_id>
      <other_id>R01-06969-20</other_id>
    </other_ids>
    <start_date>August 1997</start_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>November 20, 2008</last_update_posted>
    <locations>
      <location>Treatment Research Center, Burlington, Vermont, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000238</url>
  </study>
  <study rank="327102">
    <nct_id>NCT00000237</nct_id>
    <title>Buprenorphine Detoxification - BBDVI - 19</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Opioid-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Buprenorphine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Drug use</outcome_measure>
      <outcome_measure>Retention</outcome_measure>
      <outcome_measure>Weeks abstinent</outcome_measure>
      <outcome_measure>Weeks continuous abstinence</outcome_measure>
      <outcome_measure>Overall treatment outcome</outcome_measure>
      <outcome_measure>Opioid dependence and psychiatric status</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
      <collaborator>University of Vermont</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-06969-19</other_id>
      <other_id>R01-06969-19</other_id>
    </other_ids>
    <start_date>May 1997</start_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>August 17, 2005</last_update_posted>
    <locations>
      <location>Treatment Research Center, Burlington, Vermont, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000237</url>
  </study>
  <study rank="327103">
    <nct_id>NCT00000236</nct_id>
    <title>Buprenorphine Pharmacology Related to Addiction Treatment - 18</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Opioid-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Buprenorphine/naloxone</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Drug use</outcome_measure>
      <outcome_measure>Opioid agonist effects</outcome_measure>
      <outcome_measure>Opiate withdrawal</outcome_measure>
      <outcome_measure>Psychological changes in: pupil diameter, blood pressure, heart rate, respiration</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
      <collaborator>University of Vermont</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-06969-18</other_id>
      <other_id>R01-06969-18</other_id>
    </other_ids>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>August 17, 2005</last_update_posted>
    <locations>
      <location>Treatment Research Center, Burlington, Vermont, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000236</url>
  </study>
  <study rank="327104">
    <nct_id>NCT00000235</nct_id>
    <title>Alternate Day Buprenorphine Administration, Phase XII - 17</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Opioid-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Buprenorphine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Drug use</outcome_measure>
      <outcome_measure>Opioid withdrawal</outcome_measure>
      <outcome_measure>Opioid agonist effects</outcome_measure>
      <outcome_measure>Dose choice</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
      <collaborator>University of Vermont</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-06969-17</other_id>
      <other_id>R01-06969-17</other_id>
    </other_ids>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>August 17, 2005</last_update_posted>
    <locations>
      <location>Treatment Research Center, Burlington, Vermont, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000235</url>
  </study>
  <study rank="327105">
    <nct_id>NCT00000234</nct_id>
    <title>Alternate Day Buprenorphine Administration, Phase XI - 16</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Opioid-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Buprenorphine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Drug use</outcome_measure>
      <outcome_measure>Opioid withdrawal</outcome_measure>
      <outcome_measure>Opioid agonist effects</outcome_measure>
      <outcome_measure>Dose choice</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Vermont</lead_sponsor>
      <collaborator>National Institute on Drug Abuse (NIDA)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>25 Years</min_age>
    <max_age>51 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-06969-16</other_id>
      <other_id>R01DA006969</other_id>
      <other_id>R01-06969-16</other_id>
    </other_ids>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>May 6, 2016</last_update_posted>
    <locations>
      <location>Treatment Research Center, Burlington, Vermont, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000234</url>
  </study>
  <study rank="327106">
    <nct_id>NCT00000233</nct_id>
    <title>Alternate Day Buprenorphine Administration, Phase X - 15</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Opioid-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Buprenorphine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Opioid withdrawal</outcome_measure>
      <outcome_measure>Subjective dose estimate</outcome_measure>
      <outcome_measure>Drug effect characteristics: ARCI</outcome_measure>
      <outcome_measure>Money choice</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
      <collaborator>University of Vermont</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>34 Years</min_age>
    <max_age>51 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-06969-15</other_id>
      <other_id>R01-06969-15</other_id>
    </other_ids>
    <start_date>May 1993</start_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>August 17, 2005</last_update_posted>
    <locations>
      <location>Treatment Research Center, Burlington, Vermont, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000233</url>
  </study>
  <study rank="327107">
    <nct_id>NCT00000232</nct_id>
    <title>Alternate Day Buprenorphine Administration, Phase IX - 14</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Opioid-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Buprenorphine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Drug use</outcome_measure>
      <outcome_measure>Opioid withdrawal</outcome_measure>
      <outcome_measure>Opioid agonist effects</outcome_measure>
      <outcome_measure>Dose identification</outcome_measure>
      <outcome_measure>Pupil diameter</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Vermont</lead_sponsor>
      <collaborator>National Institute on Drug Abuse (NIDA)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>22 Years</min_age>
    <max_age>51 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-06969-14</other_id>
      <other_id>R01DA006969</other_id>
      <other_id>R01-06969-14</other_id>
    </other_ids>
    <start_date>March 1992</start_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>May 6, 2016</last_update_posted>
    <locations>
      <location>Treatment Research Center, Burlington, Vermont, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000232</url>
  </study>
  <study rank="327108">
    <nct_id>NCT00000231</nct_id>
    <title>Buprenorphine Detoxification With Two Types of Treatment. BBD IV - 13</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Opioid-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Buprenorphine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Drug use</outcome_measure>
      <outcome_measure>Retention</outcome_measure>
      <outcome_measure>Weeks abstinent</outcome_measure>
      <outcome_measure>Weeks continuous abstinence</outcome_measure>
      <outcome_measure>Overall treatment outcome</outcome_measure>
      <outcome_measure>Naltrexone consumption</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
      <collaborator>University of Vermont</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-06969-13</other_id>
      <other_id>R01-06969-13</other_id>
    </other_ids>
    <start_date>February 1992</start_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>August 17, 2005</last_update_posted>
    <locations>
      <location>Treatment Research Center, Burlington, Vermont, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000231</url>
  </study>
  <study rank="327109">
    <nct_id>NCT00000230</nct_id>
    <title>Buprenorphine Detoxification With Two Types of Treatment. BBD III - 12</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Opioid-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Buprenorphine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Drug use</outcome_measure>
      <outcome_measure>Retention</outcome_measure>
      <outcome_measure>Weeks abstinent</outcome_measure>
      <outcome_measure>Weeks continuous abstinence</outcome_measure>
      <outcome_measure>Overall treatment outcome</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Vermont</lead_sponsor>
      <collaborator>National Institute on Drug Abuse (NIDA)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-06969-12</other_id>
      <other_id>R01DA006969</other_id>
      <other_id>R01-06969-12</other_id>
    </other_ids>
    <start_date>January 1995</start_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>May 6, 2016</last_update_posted>
    <locations>
      <location>Treatment Research Center, Burlington, Vermont, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000230</url>
  </study>
  <study rank="327110">
    <nct_id>NCT00000229</nct_id>
    <title>Buprenorphine Detox With Two Types of Treatment. BBD II - 11</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Opioid-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Buprenorphine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Drug use</outcome_measure>
      <outcome_measure>Retention</outcome_measure>
      <outcome_measure>Weeks abstinent</outcome_measure>
      <outcome_measure>Weeks continuous abstinence</outcome_measure>
      <outcome_measure>Overall treatment outcome</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Vermont</lead_sponsor>
      <collaborator>National Institute on Drug Abuse (NIDA)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-06969-11</other_id>
      <other_id>R01DA006969</other_id>
      <other_id>R01-06969-11</other_id>
    </other_ids>
    <start_date>October 1995</start_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>May 6, 2016</last_update_posted>
    <locations>
      <location>Treatment Research Center, Burlington, Vermont, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000229</url>
  </study>
  <study rank="327111">
    <nct_id>NCT00000228</nct_id>
    <title>Buprenorphine Detox With Two Types of Treatment. BBD I - 10</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Opioid-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Buprenorphine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Drug use</outcome_measure>
      <outcome_measure>Retention</outcome_measure>
      <outcome_measure>Weeks abstinent</outcome_measure>
      <outcome_measure>Weeks continuous abstinence</outcome_measure>
      <outcome_measure>Overall treatment outcome</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
      <collaborator>University of Vermont</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-06969-10</other_id>
      <other_id>R01-06969-10</other_id>
    </other_ids>
    <start_date>August 1994</start_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>August 17, 2005</last_update_posted>
    <locations>
      <location>Treatment Research Center, Burlington, Vermont, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000228</url>
  </study>
  <study rank="327112">
    <nct_id>NCT00000227</nct_id>
    <title>Alternate-Day Buprenorphine Administration. Phase VIII - 9</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Opioid-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Buprenorphine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Drug use</outcome_measure>
      <outcome_measure>Opioid withdrawal</outcome_measure>
      <outcome_measure>Opioid agonist effects</outcome_measure>
      <outcome_measure>Dose choice</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Vermont</lead_sponsor>
      <collaborator>National Institute on Drug Abuse (NIDA)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>25 Years</min_age>
    <max_age>48 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-06969-9</other_id>
      <other_id>R01DA006969</other_id>
      <other_id>R01-06969-9</other_id>
    </other_ids>
    <start_date>August 1994</start_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>May 6, 2016</last_update_posted>
    <locations>
      <location>Treatment Research Center, Burlington, Vermont, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000227</url>
  </study>
  <study rank="327113">
    <nct_id>NCT00000226</nct_id>
    <title>Alternate-Day Buprenorphine Administration. Phase VII - 8</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Opioid-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Buprenorphine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Drug use</outcome_measure>
      <outcome_measure>Opioid withdrawal</outcome_measure>
      <outcome_measure>Opioid agonist effects</outcome_measure>
      <outcome_measure>Pupil diameter</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
      <collaborator>University of Vermont</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>21 Years</min_age>
    <max_age>48 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-06969-8</other_id>
      <other_id>R01-06969-8</other_id>
    </other_ids>
    <start_date>November 1994</start_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>June 24, 2005</last_update_posted>
    <locations>
      <location>Treatment Research Center, Burlington, Vermont, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000226</url>
  </study>
  <study rank="327114">
    <nct_id>NCT00000225</nct_id>
    <title>Alternate-Day Buprenorphine Administration. Phase VI - 7</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Opioid-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Buprenorphine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Drug use</outcome_measure>
      <outcome_measure>Opioid withdrawal</outcome_measure>
      <outcome_measure>Opioid agonist effects</outcome_measure>
      <outcome_measure>Dose identification</outcome_measure>
      <outcome_measure>Pupil diameter</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
      <collaborator>University of Vermont</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>21 Years</min_age>
    <max_age>51 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-06969-7</other_id>
      <other_id>R01-06969-7</other_id>
    </other_ids>
    <start_date>December 1992</start_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>June 24, 2005</last_update_posted>
    <locations>
      <location>Treatment Research Center, Burlington, Vermont, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000225</url>
  </study>
  <study rank="327115">
    <nct_id>NCT00000224</nct_id>
    <title>Alternate-Day Buprenorphine. Phase V - 6</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Opioid-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Buprenorphine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Drug use</outcome_measure>
      <outcome_measure>Opioid withdrawal</outcome_measure>
      <outcome_measure>Subjective dose estimate</outcome_measure>
      <outcome_measure>Drug effect characteristics: ARCI</outcome_measure>
      <outcome_measure>Physiological changes in: pupil diameter</outcome_measure>
      <outcome_measure>Physiological changes in: blood pressure</outcome_measure>
      <outcome_measure>Physiological changes in: heart rate</outcome_measure>
      <outcome_measure>Physiological changes in: respiration</outcome_measure>
      <outcome_measure>Physiological changes in: bup plasma levels</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
      <collaborator>University of Vermont</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>30 Years</min_age>
    <max_age>49 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-06969-6</other_id>
      <other_id>R01-06969-6</other_id>
    </other_ids>
    <start_date>February 1993</start_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>June 24, 2005</last_update_posted>
    <locations>
      <location>Treatment Research Center, Burlington, Vermont, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000224</url>
  </study>
  <study rank="327116">
    <nct_id>NCT00000223</nct_id>
    <title>Alternate-Day Buprenorphine Administration. Phase IV - 5</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Opioid-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Buprenorphine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Drug use</outcome_measure>
      <outcome_measure>Opioid withdrawal</outcome_measure>
      <outcome_measure>Opioid agonist effects</outcome_measure>
      <outcome_measure>Dose identification</outcome_measure>
      <outcome_measure>Pupil diameter</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
      <collaborator>University of Vermont</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>20 Years</min_age>
    <max_age>49 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-06969-5</other_id>
      <other_id>R01-06969-5</other_id>
    </other_ids>
    <start_date>June 1993</start_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>June 24, 2005</last_update_posted>
    <locations>
      <location>Treatment Research Center, Burlington, Vermont, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000223</url>
  </study>
  <study rank="327117">
    <nct_id>NCT00000222</nct_id>
    <title>Alternate-Day Buprenorphine Administration. Phase II - 4</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Opioid-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Buprenorphine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Drug use</outcome_measure>
      <outcome_measure>Opioid withdrawal</outcome_measure>
      <outcome_measure>Opioid agonist effects</outcome_measure>
      <outcome_measure>Dose identification</outcome_measure>
      <outcome_measure>Pupil diameter</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
      <collaborator>University of Vermont</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>28 Years</min_age>
    <max_age>45 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-06969-4</other_id>
      <other_id>R01-06969-4</other_id>
    </other_ids>
    <start_date>July 1992</start_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>June 24, 2005</last_update_posted>
    <locations>
      <location>Treatment Research Center, Burlington, Vermont, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000222</url>
  </study>
  <study rank="327118">
    <nct_id>NCT00000221</nct_id>
    <title>Alternate-Day Buprenorphine Administration. Phase I - 3</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Opioid-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Buprenorphine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Drug use</outcome_measure>
      <outcome_measure>Opioid withdrawal</outcome_measure>
      <outcome_measure>Opioid agonist effects</outcome_measure>
      <outcome_measure>Dose identification</outcome_measure>
      <outcome_measure>Pupil diameter</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
      <collaborator>University of Vermont</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>28 Years</min_age>
    <max_age>45 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-06969-3</other_id>
      <other_id>R01-06969-3</other_id>
    </other_ids>
    <start_date>April 1992</start_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>June 24, 2005</last_update_posted>
    <locations>
      <location>Treatment Research Center, Burlington, Vermont, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000221</url>
  </study>
  <study rank="327119">
    <nct_id>NCT00000220</nct_id>
    <title>Gradual Vs. Rapid Buprenorphine Detoxification - 2</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Opioid-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Buprenorphine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Drug use</outcome_measure>
      <outcome_measure>Retention</outcome_measure>
      <outcome_measure>Observed withdrawal rating</outcome_measure>
      <outcome_measure>Opioid agonist rating</outcome_measure>
      <outcome_measure>Opioid antagonist rating</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
      <collaborator>University of Vermont</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>33 Years</min_age>
    <max_age>43 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-06969-2</other_id>
      <other_id>R01-06969-2</other_id>
    </other_ids>
    <start_date>June 1991</start_date>
    <completion_date>July 2001</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>June 24, 2005</last_update_posted>
    <locations>
      <location>Treatment Research Center, Burlington, Vermont, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000220</url>
  </study>
  <study rank="327120">
    <nct_id>NCT00000219</nct_id>
    <title>Buprenorphine Dose Alteration Study - 1</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Opioid-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Buprenorphine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Opioid withdrawal</outcome_measure>
      <outcome_measure>Subjective dose estimate</outcome_measure>
      <outcome_measure>Drug effect characteristics: ARCI</outcome_measure>
      <outcome_measure>Physiological changes in: pupil diameter</outcome_measure>
      <outcome_measure>Physiological changes in: blood pressure</outcome_measure>
      <outcome_measure>Physiological changes in: heart rate</outcome_measure>
      <outcome_measure>Physiological changes in: respiration</outcome_measure>
      <outcome_measure>Physiological changes in: skin temperature</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Vermont</lead_sponsor>
      <collaborator>National Institute on Drug Abuse (NIDA)</collaborator>
    </sponsors>
    <gender>Male</gender>
    <min_age>19 Years</min_age>
    <max_age>41 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-06969-1</other_id>
      <other_id>R18DA006969</other_id>
      <other_id>R01-06969-1</other_id>
    </other_ids>
    <start_date>December 1991</start_date>
    <completion_date>July 2001</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>May 6, 2016</last_update_posted>
    <locations>
      <location>Treatment Research Center, Burlington, Vermont, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000219</url>
  </study>
  <study rank="327121">
    <nct_id>NCT00000218</nct_id>
    <title>Pharmacotherapy and Intensive Treatment - 2</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cocaine-Related Disorders</condition>
      <condition>Substance-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Carbamazepine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Severity addiction</outcome_measure>
      <outcome_measure>Depression</outcome_measure>
      <outcome_measure>Depression, anxiety</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
      <collaborator>VA Office of Research and Development</collaborator>
    </sponsors>
    <gender>Female</gender>
    <min_age>18 Years</min_age>
    <max_age>60 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>353</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>U.S. Fed</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-06954-2</other_id>
      <other_id>R18-06954-2</other_id>
    </other_ids>
    <completion_date>June 2005</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>January 12, 2017</last_update_posted>
    <locations>
      <location>University of Kansas, Kansas City, Missouri, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000218</url>
  </study>
  <study rank="327122">
    <nct_id>NCT00000217</nct_id>
    <title>Pharmacotherapy and Intensive Treatment of Drug Abuse - 1</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cocaine-Related Disorders</condition>
      <condition>Substance-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Carbamazepine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Drug use</outcome_measure>
      <outcome_measure>Effectiveness of medication</outcome_measure>
      <outcome_measure>Level of pharm</outcome_measure>
      <outcome_measure>Retention</outcome_measure>
      <outcome_measure>Depression, anxiety</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Kansas</lead_sponsor>
      <collaborator>National Institute on Drug Abuse (NIDA)</collaborator>
      <collaborator>US Department of Veterans Affairs</collaborator>
      <collaborator>University of Kansas Medical Center</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>60 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
      <funded_by>U.S. Fed</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-06954-1</other_id>
      <other_id>R18DA006954</other_id>
      <other_id>R18-06954-1</other_id>
    </other_ids>
    <start_date>September 1990</start_date>
    <primary_completion_date>October 1996</primary_completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>April 16, 2015</last_update_posted>
    <locations>
      <location>University of Kansas, Kansas City, Missouri, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000217</url>
  </study>
  <study rank="327123">
    <nct_id>NCT00000216</nct_id>
    <title>Buprenorphine Maintenance for Cocaine Abusing Opioid Addicts - 1</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cocaine-Related Disorders</condition>
      <condition>Opioid-Related Disorders</condition>
      <condition>Substance-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Buprenorphine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Depression</outcome_measure>
      <outcome_measure>Withdrawal symptoms</outcome_measure>
      <outcome_measure>Opioid and cocaine use</outcome_measure>
      <outcome_measure>Social and psychological functioning</outcome_measure>
      <outcome_measure>AIDS risk behavior</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
      <collaborator>Yale University</collaborator>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-06266-1</other_id>
      <other_id>R01-06266-1</other_id>
    </other_ids>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>August 17, 2005</last_update_posted>
    <locations>
      <location>APT Residential Services Division, New Haven, Connecticut, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000216</url>
  </study>
  <study rank="327124">
    <nct_id>NCT00000215</nct_id>
    <title>IV Cocaine Abuse: A Laboratory Model - 4</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cocaine-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Pergolide</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Direct cocaine effects (cardio, subjective)</outcome_measure>
      <outcome_measure>Interaction of cocaine/pergolide on cardio</outcome_measure>
      <outcome_measure>Interaction of coc/pergolide on coc's subjective</outcome_measure>
      <outcome_measure>Effects of pergolide on cocaine craving</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
      <collaborator>Columbia University</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>45 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-06234-4</other_id>
      <other_id>R01-06234-4</other_id>
    </other_ids>
    <completion_date>December 2001</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>January 12, 2017</last_update_posted>
    <locations>
      <location>Columbia University, New York, New York, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000215</url>
  </study>
  <study rank="327125">
    <nct_id>NCT00000214</nct_id>
    <title>IV Cocaine Abuse: A Laboratory Model - 3</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cocaine-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Buprenorphine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Direct cocaine effects (caridio, subjective)</outcome_measure>
      <outcome_measure>Interaction of coc/bup on cardio measures</outcome_measure>
      <outcome_measure>Ineraction of coc/bup on coc's subjective effects</outcome_measure>
      <outcome_measure>Effects of buprenorphine on cocaine craving</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>New York State Psychiatric Institute</lead_sponsor>
      <collaborator>National Institute on Drug Abuse (NIDA)</collaborator>
      <collaborator>Columbia University</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>45 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-06234-3</other_id>
      <other_id>R01DA006234</other_id>
      <other_id>R01-06234-3</other_id>
    </other_ids>
    <start_date>January 1992</start_date>
    <primary_completion_date>January 1993</primary_completion_date>
    <completion_date>January 1993</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>August 31, 2015</last_update_posted>
    <locations>
      <location>Columbia University, New York, New York, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000214</url>
  </study>
  <study rank="327126">
    <nct_id>NCT00000213</nct_id>
    <title>IV Cocaine Abuse: A Laboratory Model - 2</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cocaine-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Fluoxetine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Direct cocaine effects</outcome_measure>
      <outcome_measure>Interaction of cocaine/fluox. on cardio measures</outcome_measure>
      <outcome_measure>Interaction of cocaine/fluox. on coc's subjective</outcome_measure>
      <outcome_measure>Effects of fluoxetine on cocaine craving</outcome_measure>
      <outcome_measure>Drug use during outpatient fluoxetine maintenance</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>New York State Psychiatric Institute</lead_sponsor>
      <collaborator>National Institute on Drug Abuse (NIDA)</collaborator>
      <collaborator>Columbia University</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>45 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-06234-2</other_id>
      <other_id>R01DA006234</other_id>
      <other_id>R01-06234-2</other_id>
    </other_ids>
    <start_date>April 1990</start_date>
    <primary_completion_date>April 1991</primary_completion_date>
    <completion_date>April 1991</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>August 28, 2015</last_update_posted>
    <locations>
      <location>Columbia University, New York, New York, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000213</url>
  </study>
  <study rank="327127">
    <nct_id>NCT00000212</nct_id>
    <title>IV Cocaine Abuse: A Laboratory Model - 1</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cocaine-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Desipramine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Amount cocaine self-administered</outcome_measure>
      <outcome_measure>Direct cocaine effects (cardiovascular, subjective</outcome_measure>
      <outcome_measure>Interaction of cocaine and DMI on cardio measures</outcome_measure>
      <outcome_measure>Interaction of cocaine/DMI on coc's subjective</outcome_measure>
      <outcome_measure>Effects of DMI on cocaine craving</outcome_measure>
      <outcome_measure>Drug use during outpatient DMI maintenance</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>New York State Psychiatric Institute</lead_sponsor>
      <collaborator>National Institute on Drug Abuse (NIDA)</collaborator>
      <collaborator>Columbia University</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>45 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-06234-1</other_id>
      <other_id>R01DA006234</other_id>
      <other_id>R01-06234-1</other_id>
    </other_ids>
    <start_date>July 1987</start_date>
    <primary_completion_date>July 1988</primary_completion_date>
    <completion_date>July 1988</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>August 31, 2015</last_update_posted>
    <locations>
      <location>Columbia University, New York, New York, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000212</url>
  </study>
  <study rank="327128">
    <nct_id>NCT00000211</nct_id>
    <title>Treatment Efficacy for Drug Abuse and AIDS Prevention - 2</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cocaine-Related Disorders</condition>
      <condition>Heroin Dependence</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Buprenorphine</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
      <collaborator>Mclean Hospital</collaborator>
    </sponsors>
    <gender>Male</gender>
    <min_age>26 Years</min_age>
    <max_age>41 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-06116-2</other_id>
      <other_id>R18-06116-2</other_id>
    </other_ids>
    <start_date>September 1989</start_date>
    <primary_completion_date>February 1996</primary_completion_date>
    <completion_date>February 1996</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>January 12, 2017</last_update_posted>
    <locations>
      <location>McLean Hospital, Dept. of Psychiatry, Belmont, Massachusetts, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000211</url>
  </study>
  <study rank="327129">
    <nct_id>NCT00000210</nct_id>
    <title>Treatment Efficacy for Drug Abuse and AIDS Prevention - 1</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cocaine-Related Disorders</condition>
      <condition>Heroin Dependence</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Buprenorphine</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
      <collaborator>Mclean Hospital</collaborator>
    </sponsors>
    <gender>Male</gender>
    <min_age>26 Years</min_age>
    <max_age>41 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-06116-1</other_id>
      <other_id>R18-06116-1</other_id>
    </other_ids>
    <start_date>September 1989</start_date>
    <primary_completion_date>February 1996</primary_completion_date>
    <completion_date>February 1996</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>January 12, 2017</last_update_posted>
    <locations>
      <location>McLean Hospital, Dept. of Psychiatry, Belmont, Massachusetts, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000210</url>
  </study>
  <study rank="327130">
    <nct_id>NCT00000209</nct_id>
    <title>Buprenorphine Dosing Interval - 5</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Opioid-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Buprenorphine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Drug use</outcome_measure>
      <outcome_measure>Withdrawal symptoms</outcome_measure>
      <outcome_measure>Opiate and cocaine craving</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>21 Years</min_age>
    <max_age>50 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Masking: Single</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-06082-5</other_id>
      <other_id>R18-06082-5</other_id>
    </other_ids>
    <start_date>November 1992</start_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>August 17, 2005</last_update_posted>
    <locations>
      <location>Friends Research Institute, Los Angeles, California, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000209</url>
  </study>
  <study rank="327131">
    <nct_id>NCT00000208</nct_id>
    <title>Methadone/Buprenorphine Cross-Over Study - 4</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Opioid-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Buprenorphine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Drug use</outcome_measure>
      <outcome_measure>Withdrawal symptoms</outcome_measure>
      <outcome_measure>Opiate craving</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>21 Years</min_age>
    <max_age>50 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-06082-4</other_id>
      <other_id>R18-06082-4</other_id>
    </other_ids>
    <start_date>February 1992</start_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>August 17, 2005</last_update_posted>
    <locations>
      <location>Friends Research Institute, Los Angeles, California, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000208</url>
  </study>
  <study rank="327132">
    <nct_id>NCT00000207</nct_id>
    <title>Multicenter Clinical Trial of Buprenorphine - 3</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Opioid-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Buprenorphine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Retention</outcome_measure>
      <outcome_measure>Opiate use</outcome_measure>
      <outcome_measure>Opiate craving</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of California, Los Angeles</lead_sponsor>
      <collaborator>National Institute on Drug Abuse (NIDA)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>21 Years</min_age>
    <max_age>50 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-06082-3</other_id>
      <other_id>R18DA006082</other_id>
      <other_id>R18-06082-3</other_id>
    </other_ids>
    <start_date>May 1992</start_date>
    <primary_completion_date>April 1997</primary_completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>July 11, 2016</last_update_posted>
    <locations>
      <location>Friends Research Institute, Los Angeles, California, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000207</url>
  </study>
  <study rank="327133">
    <nct_id>NCT00000206</nct_id>
    <title>Clinical Rescue Protocol - 2</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Opioid-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Buprenorphine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Retention</outcome_measure>
      <outcome_measure>Opiate use</outcome_measure>
      <outcome_measure>Opiate craving</outcome_measure>
      <outcome_measure>Adverse events</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of California, Los Angeles</lead_sponsor>
      <collaborator>National Institute on Drug Abuse (NIDA)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>21 Years</min_age>
    <max_age>50 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-06082-2</other_id>
      <other_id>R18DA006082</other_id>
      <other_id>R18-06082-2</other_id>
    </other_ids>
    <start_date>April 1991</start_date>
    <primary_completion_date>August 2005</primary_completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>November 7, 2016</last_update_posted>
    <locations>
      <location>Friends Research Institute, Los Angeles, California, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000206</url>
  </study>
  <study rank="327134">
    <nct_id>NCT00000205</nct_id>
    <title>Buprenorphine Maintenance Protocol - 1</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Opioid-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Buprenorphine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Retention</outcome_measure>
      <outcome_measure>Opiate use</outcome_measure>
      <outcome_measure>Opiate craving</outcome_measure>
      <outcome_measure>Adverse events</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of California, Los Angeles</lead_sponsor>
      <collaborator>National Institute on Drug Abuse (NIDA)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>21 Years</min_age>
    <max_age>50 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-06082-1</other_id>
      <other_id>R18DA006082</other_id>
      <other_id>R18-06082-1</other_id>
    </other_ids>
    <start_date>October 1990</start_date>
    <primary_completion_date>March 1993</primary_completion_date>
    <completion_date>September 1993</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>July 11, 2016</last_update_posted>
    <locations>
      <location>Friends Research Institute, Los Angeles, California, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000205</url>
  </study>
  <study rank="327135">
    <nct_id>NCT00000204</nct_id>
    <title>Buprenorphine Maintenance for Opioid Addicts - 3</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Opioid-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Buprenorphine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Drug use</outcome_measure>
      <outcome_measure>Retention</outcome_measure>
      <outcome_measure>Withdrawal symptoms</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Yale University</lead_sponsor>
      <collaborator>National Institute on Drug Abuse (NIDA)</collaborator>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-05626-3</other_id>
      <other_id>R01DA005626</other_id>
      <other_id>R01-05626-3</other_id>
    </other_ids>
    <start_date>August 1988</start_date>
    <primary_completion_date>May 2006</primary_completion_date>
    <completion_date>May 2006</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>July 25, 2013</last_update_posted>
    <locations>
      <location>VA Connecticut Healthcare System, New Haven, Connecticut, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000204</url>
  </study>
  <study rank="327136">
    <nct_id>NCT00000203</nct_id>
    <title>Buprenorphine Maintenance for Opioid Addicts - 2</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Opioid-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Buprenorphine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Drug use</outcome_measure>
      <outcome_measure>Withdrawal symptoms</outcome_measure>
      <outcome_measure>Psychological symptoms</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Yale University</lead_sponsor>
      <collaborator>National Institute on Drug Abuse (NIDA)</collaborator>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-05626-2</other_id>
      <other_id>R01DA005626</other_id>
      <other_id>R01-05626-2</other_id>
    </other_ids>
    <start_date>August 1988</start_date>
    <primary_completion_date>May 2006</primary_completion_date>
    <completion_date>May 2006</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>July 25, 2013</last_update_posted>
    <locations>
      <location>VA Connecticut Healthcare System, New Haven, Connecticut, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000203</url>
  </study>
  <study rank="327137">
    <nct_id>NCT00000202</nct_id>
    <title>Buprenorphine Maintenance for Opioid Addicts - 1</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Opioid-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Buprenorphine</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>Yale University</lead_sponsor>
      <collaborator>National Institute on Drug Abuse (NIDA)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-05626-1</other_id>
      <other_id>R01DA005626</other_id>
      <other_id>R01-05626-1</other_id>
    </other_ids>
    <start_date>August 1988</start_date>
    <primary_completion_date>May 2006</primary_completion_date>
    <completion_date>May 2006</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>July 25, 2013</last_update_posted>
    <locations>
      <location>VA Connecticut Healthcare System, New Haven, Connecticut, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000202</url>
  </study>
  <study rank="327138">
    <nct_id>NCT00000201</nct_id>
    <title>Pharmacological Modulation of Cocaine Effects - 1</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cocaine-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Selegiline</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
      <collaborator>Johns Hopkins University</collaborator>
    </sponsors>
    <gender>Female</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-05196-1</other_id>
      <other_id>R01-05196-1</other_id>
    </other_ids>
    <completion_date>December 2001</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>January 12, 2017</last_update_posted>
    <locations>
      <location>Johns Hopkins University (BPRU) Bayview Campus, Baltimore, Maryland, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000201</url>
  </study>
  <study rank="327139">
    <nct_id>NCT00000200</nct_id>
    <title>Cocaine Effects in Humans: Physiology and Behavior - 1</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cocaine-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Methadone</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Interaction of cocaine and meds on cardio</outcome_measure>
      <outcome_measure>Interaction of cocaine &amp; meds on coc's subjective</outcome_measure>
      <outcome_measure>Effects of medication on cocaine craving</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
      <collaborator>Columbia University</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>45 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>19</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Double (Participant, Care Provider)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-03818-1</other_id>
      <other_id>R01-03818-1</other_id>
    </other_ids>
    <start_date>January 1997</start_date>
    <primary_completion_date>January 1998</primary_completion_date>
    <completion_date>January 1998</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>January 12, 2017</last_update_posted>
    <locations>
      <location>Columbia University, New York, New York, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000200</url>
  </study>
  <study rank="327140">
    <nct_id>NCT00000199</nct_id>
    <title>Piracetam for Treatment of Cocaine Addiction, Phase II - 4</title>
    <acronym/>
    <status open="N">Withdrawn</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cocaine-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Piracetam</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Drug use</outcome_measure>
      <outcome_measure>Adverse effects</outcome_measure>
      <outcome_measure>Clinical status</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Pennsylvania</lead_sponsor>
      <collaborator>National Institute on Drug Abuse (NIDA)</collaborator>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-00238-4</other_id>
      <other_id>K20DA000238</other_id>
      <other_id>K02-00238-4</other_id>
    </other_ids>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>March 30, 2017</last_update_posted>
    <locations>
      <location>University of Pennsylvania, Philadelphia, Pennsylvania, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000199</url>
  </study>
  <study rank="327141">
    <nct_id>NCT00000198</nct_id>
    <title>Piracetam for Treatment of Cocaine Addiction - 3</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cocaine-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Piracetam</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Pulse, blood pressure</outcome_measure>
      <outcome_measure>Adverse effects</outcome_measure>
      <outcome_measure>High, anxiety, withdrawal</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Pennsylvania</lead_sponsor>
      <collaborator>National Institute on Drug Abuse (NIDA)</collaborator>
    </sponsors>
    <gender>Male</gender>
    <min_age>21 Years</min_age>
    <max_age>45 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-00238-3</other_id>
      <other_id>K20DA000238</other_id>
      <other_id>K02-00238-3</other_id>
    </other_ids>
    <start_date>October 1996</start_date>
    <primary_completion_date>October 1997</primary_completion_date>
    <completion_date>October 1997</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>October 6, 2015</last_update_posted>
    <locations>
      <location>University of Pennsylvania, Philadelphia, Pennsylvania, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000198</url>
  </study>
  <study rank="327142">
    <nct_id>NCT00000197</nct_id>
    <title>Propranolol for Treatment of Cocaine Addiction - 2</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cocaine-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Propranolol</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Side effects</outcome_measure>
      <outcome_measure>Cocaine use</outcome_measure>
      <outcome_measure>Cocaine withdrawal</outcome_measure>
      <outcome_measure>Cocaine craving</outcome_measure>
      <outcome_measure>Mood and anxiety</outcome_measure>
      <outcome_measure>Clinical improvement</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
      <collaborator>University of Pennsylvania</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>25 Years</min_age>
    <max_age>49 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-00238-2</other_id>
      <other_id>K20DA000238</other_id>
    </other_ids>
    <start_date>January 1987</start_date>
    <primary_completion_date>January 2002</primary_completion_date>
    <completion_date>January 2002</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>January 12, 2017</last_update_posted>
    <locations>
      <location>University of Pennsylvania, Philadelphia, Pennsylvania, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000197</url>
  </study>
  <study rank="327143">
    <nct_id>NCT00000196</nct_id>
    <title>Neurobiology of Opioid Dependence: 5 - 5</title>
    <acronym/>
    <status open="N">Withdrawn</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Opioid-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Naltrexone</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Behavioral, physiological, neuroendocrine response to yohimbine</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Yale University</lead_sponsor>
      <collaborator>National Institute on Drug Abuse (NIDA)</collaborator>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-00191-5</other_id>
      <other_id>K20DA000191</other_id>
      <other_id>K20-00191-5</other_id>
    </other_ids>
    <start_date>January 1993</start_date>
    <primary_completion_date>January 1998</primary_completion_date>
    <completion_date>January 1998</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>June 3, 2015</last_update_posted>
    <locations>
      <location>VA Connecticut Healthcare System, New Haven, Connecticut, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000196</url>
  </study>
  <study rank="327144">
    <nct_id>NCT00000195</nct_id>
    <title>Neurobiology of Opioid Dependence: 4 - 4</title>
    <acronym/>
    <status open="N">Withdrawn</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Opioid-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Naltrexone</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Behavioral, physiological, neuroendocrine response to yohimine</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Yale University</lead_sponsor>
      <collaborator>National Institute on Drug Abuse (NIDA)</collaborator>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-00191-4</other_id>
      <other_id>K20DA000191</other_id>
      <other_id>K20-00191-4</other_id>
    </other_ids>
    <start_date>January 1993</start_date>
    <primary_completion_date>January 1998</primary_completion_date>
    <completion_date>January 1998</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>May 6, 2016</last_update_posted>
    <locations>
      <location>VA Connecticut Healthcare System, New Haven, Connecticut, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000195</url>
  </study>
  <study rank="327145">
    <nct_id>NCT00000194</nct_id>
    <title>Neurobiology of Opioid Dependence: 3 - 3</title>
    <acronym/>
    <status open="N">Withdrawn</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Opioid-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Cycloserine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Behavioral, subjective, measures of naloxone-preci</outcome_measure>
      <outcome_measure>Phsyiological, neuroendocrine measures of naloxone</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Yale University</lead_sponsor>
      <collaborator>National Institute on Drug Abuse (NIDA)</collaborator>
    </sponsors>
    <gender>Male</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-00191-3</other_id>
      <other_id>K20DA000191</other_id>
      <other_id>K20-00191-3</other_id>
    </other_ids>
    <start_date>January 1993</start_date>
    <primary_completion_date>January 1998</primary_completion_date>
    <completion_date>January 1998</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>May 6, 2016</last_update_posted>
    <locations>
      <location>VA Connecticut Healthcare System, New Haven, Connecticut, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000194</url>
  </study>
  <study rank="327146">
    <nct_id>NCT00000193</nct_id>
    <title>Neurobiology of Opioid Dependence: 2 - 2</title>
    <acronym/>
    <status open="N">Withdrawn</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Opioid-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Gamma hydroxybutyric</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Behavioral, subjective, measures of naloxone-preci</outcome_measure>
      <outcome_measure>Phsyiological, neuroendocrine measures of naloxone</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Yale University</lead_sponsor>
      <collaborator>National Institute on Drug Abuse (NIDA)</collaborator>
    </sponsors>
    <gender>Male</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-00191-2</other_id>
      <other_id>K20DA000191</other_id>
      <other_id>K20-00191-2</other_id>
    </other_ids>
    <start_date>January 1993</start_date>
    <primary_completion_date>January 1998</primary_completion_date>
    <completion_date>January 1998</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>August 7, 2015</last_update_posted>
    <locations>
      <location>VA Connecticut Healthcare System, New Haven, Connecticut, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000193</url>
  </study>
  <study rank="327147">
    <nct_id>NCT00000192</nct_id>
    <title>Neurobiology of Opioid Dependence: 1 - 1</title>
    <acronym/>
    <status open="N">Withdrawn</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Opioid-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Lamotrigine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Behavioral, subjective, measures of naloxone-precipitated opiate withdrawal</outcome_measure>
      <outcome_measure>Phsyiological, neuroendocrine measures of naloxone-precipitated opiate withdrawal</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Yale University</lead_sponsor>
      <collaborator>National Institute on Drug Abuse (NIDA)</collaborator>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-00191-1</other_id>
      <other_id>K20DA000191</other_id>
      <other_id>K20-00191-1</other_id>
    </other_ids>
    <start_date>January 1993</start_date>
    <primary_completion_date>January 1998</primary_completion_date>
    <completion_date>January 1998</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>August 7, 2015</last_update_posted>
    <locations>
      <location>VA Connecticut Healthcare System, New Haven, Connecticut, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000192</url>
  </study>
  <study rank="327148">
    <nct_id>NCT00000191</nct_id>
    <title>Carbamazepine Treatment for Cocaine Dependence - 5</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cocaine-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Carbamazepine</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>University of Pennsylvania</lead_sponsor>
      <collaborator>National Institute on Drug Abuse (NIDA)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>21 Years</min_age>
    <max_age>51 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-00144-5</other_id>
      <other_id>3R01DA012268</other_id>
      <other_id>K20-00144-5</other_id>
    </other_ids>
    <start_date>January 1991</start_date>
    <primary_completion_date>February 1994</primary_completion_date>
    <completion_date>February 1994</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>May 28, 2015</last_update_posted>
    <locations>
      <location>University of Pennsylvania, Philadelphia, Pennsylvania, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000191</url>
  </study>
  <study rank="327149">
    <nct_id>NCT00000190</nct_id>
    <title>Cocaine in Parotid Saliva, Blood and Urine - 4</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cocaine-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">Parotid Gland</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Cocaine &amp; benzoylecgonine content in saliva, plasma, &amp; urine</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Pennsylvania</lead_sponsor>
      <collaborator>National Institute on Drug Abuse (NIDA)</collaborator>
    </sponsors>
    <gender>Male</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Diagnostic</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-00144-4</other_id>
      <other_id>3R01DA012268</other_id>
      <other_id>K20-00144-4</other_id>
    </other_ids>
    <start_date>January 1991</start_date>
    <primary_completion_date>February 1992</primary_completion_date>
    <completion_date>February 1992</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>May 28, 2015</last_update_posted>
    <locations>
      <location>University of Pennsylvania, Philadelphia, Pennsylvania, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000190</url>
  </study>
  <study rank="327150">
    <nct_id>NCT00000189</nct_id>
    <title>Gepirone vs Placebo in Treatment of Cocaine Dependence - 3</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cocaine-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Gepirone</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>University of Pennsylvania</lead_sponsor>
      <collaborator>National Institute on Drug Abuse (NIDA)</collaborator>
    </sponsors>
    <gender>Male</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>41</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-00144-3</other_id>
      <other_id>3R01DA012268</other_id>
      <other_id>K20-00144-3</other_id>
    </other_ids>
    <start_date>January 1990</start_date>
    <primary_completion_date>February 1991</primary_completion_date>
    <completion_date>February 1991</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>May 28, 2015</last_update_posted>
    <locations>
      <location>University of Pennsylvania, Philadelphia, Pennsylvania, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000189</url>
  </study>
  <study rank="327151">
    <nct_id>NCT00000188</nct_id>
    <title>Selegiline in Treatment of Cocaine Dependence - 2</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cocaine-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Selegiline</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Retention</outcome_measure>
      <outcome_measure>Cocaine use</outcome_measure>
      <outcome_measure>Cocaine craving</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Pennsylvania</lead_sponsor>
      <collaborator>National Institute on Drug Abuse (NIDA)</collaborator>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>50</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-00144-2</other_id>
      <other_id>3R01DA012268</other_id>
      <other_id>K20-00144-2</other_id>
    </other_ids>
    <start_date>September 1994</start_date>
    <primary_completion_date>October 1995</primary_completion_date>
    <completion_date>October 1995</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>May 28, 2015</last_update_posted>
    <locations>
      <location>PDVAMC Treatment Research Center, Philadelphia, Pennsylvania, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000188</url>
  </study>
  <study rank="327152">
    <nct_id>NCT00000187</nct_id>
    <title>Ritanserin in Treatment of Cocaine Dependence - 1</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cocaine-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ritanserin</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Cocaine use</outcome_measure>
      <outcome_measure>Cocaine craving</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Pennsylvania</lead_sponsor>
      <collaborator>National Institute on Drug Abuse (NIDA)</collaborator>
    </sponsors>
    <gender>Male</gender>
    <min_age>28 Years</min_age>
    <max_age>47 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>80</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-00144-1</other_id>
      <other_id>3R01DA012268</other_id>
      <other_id>K20-00144-1</other_id>
    </other_ids>
    <start_date>July 1992</start_date>
    <primary_completion_date>June 1994</primary_completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>May 28, 2015</last_update_posted>
    <locations>
      <location>University of Pennsylvania, Philadelphia, Pennsylvania, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000187</url>
  </study>
  <study rank="327153">
    <nct_id>NCT00004640</nct_id>
    <title>&quot;Clinical Trials to Enhance Elders' Oral Health&quot; (&quot;TEETH&quot;)</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Tooth Loss</condition>
      <condition>Periodontal Disease</condition>
      <condition>Tooth Decay</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Chlorhexidine rinse</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>regular rinsing with chlorhexidine is effective method for reducing the incidence of tooth loss in low income older adults.</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Washington</lead_sponsor>
      <collaborator>National Institute of Dental and Craniofacial Research (NIDCR)</collaborator>
      <collaborator>Colgate Palmolive</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>60 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>1101</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDCR-008</other_id>
      <other_id>R01DE012215</other_id>
    </other_ids>
    <start_date>May 1998</start_date>
    <primary_completion_date>May 2008</primary_completion_date>
    <completion_date>October 2008</completion_date>
    <study_first_posted>September 20, 1999</study_first_posted>
    <last_update_posted>June 20, 2012</last_update_posted>
    <locations>
      <location>University of Washington, Seattle, Washington, United States</location>
      <location>University of British Columbia, Vancouver, British Columbia, Canada</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004640</url>
  </study>
  <study rank="327154">
    <nct_id>NCT00004639</nct_id>
    <title>Cleft Palate Surgery and Speech Development</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cleft Lip</condition>
      <condition>Cleft Palate</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">Furlow double z-plasty palatoplasty palate repair</intervention>
      <intervention type="Procedure">Von Langenbeck palatoplasty palate repair</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Velopharyngeal function for speech was identified to be better for patients who received the Furlow double opposing z-palatoplasty procedure than patients who received the von Langenbeck procedure, as determined by the Cul-de-Sac Test of Hypernasality.</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Florida</lead_sponsor>
      <collaborator>University of Sao Paulo</collaborator>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>475</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDCR-010</other_id>
      <other_id>R01DE010437</other_id>
    </other_ids>
    <start_date>February 1996</start_date>
    <primary_completion_date>March 2006</primary_completion_date>
    <completion_date>April 2007</completion_date>
    <study_first_posted>September 20, 1999</study_first_posted>
    <last_update_posted>September 20, 2011</last_update_posted>
    <locations>
      <location>University of Florida, Gainesville, Florida, United States</location>
      <location>Hospital for Rehabilitation of Craniofacial Anomalies (USP-HRAC), Bauru, Sao Paulo, Brazil</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004639</url>
  </study>
</search_results>
